| HSPMDB000001 | 16982771 | Hsp70 | GRP78 | Human | Endoplasmic Reticulum | Inhibition of ATPase activity | Sensitizes human breast cancer cells to etoposide | (-)-Epigallocatechin Gallate (EGCG) | [(2~{R},3~{R})-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2~{H}-chromen-3-yl] 3,4,5-trihydroxybenzoate | C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O | Polyphenol | 61% inhibition at 10 uM | 0.7 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | FACS |
| HSPMDB000002 | 16982771 | Hsp70 | GRP78 | Human | Endoplasmic Reticulum | Inhibition of ATPase activity | NA | (-)-epicatechin (EC) | (2~{R},3~{R})-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2~{H}-chromene-3,5,7-triol | C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O | Polyphenol | 38% inhibition at 10 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000003 | 16982771 | Hsp70 | GRP78 | Human | Endoplasmic Reticulum | Inhibition of ATPase activity | NA | (-)-epicatechin-3-gallate (ECG) | [(2~{R},3~{R})-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2~{H}-chromen-3-yl] 3,4,5-trihydroxybenzoate | C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O | Polyphenol | 64% inhibition at 10 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000004 | 16982771 | Hsp70 | GRP78 | Human | Endoplasmic Reticulum | Inhibition of ATPase activity | NA | (-)-epigallocatechin (EGC) | (2~{R},3~{R})-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2~{H}-chromene-3,5,7-triol | C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)O | Polyphenol | 58% inhibition at 10 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000005 | 19793966 | Hsp70 | Hsc70/ DnaJ | Human | Cytosol and nucleus | Inhibition of ATPase activity | Decreases total tau levels in cells overexpressing human tau protein | Methylene blue (MB) | [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride | CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] | Dihydropyrimidine derivative | > 80% | NA | NA | 83 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000006 | 19793966 | Hsp70 | Hsc70/ DnaJ | Human | Cytosol and nucleus | Inhibition of ATPase activity | Decreases total tau levels in cells overexpressing human tau protein | Azure C (AC) | 7-methyliminophenothiazin-10-ium-3-amine;chloride | CN=C1C=CC2=[NH+]C3=C(C=C(C=C3)N)SC2=C1.[Cl-] | Dihydropyrimidine derivative | > 80% | NA | NA | 11 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000007 | 19793966 | Hsp70 | Hsc70/ DnaJ | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | Myricetin (MY) | 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one | C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O | Dihydropyrimidine derivative | > 80% | NA | NA | 12 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000008 | 19793966 | Hsp70 | Hsc70/ DnaJ | Human | Cytosol and nucleus | Activation of ATPase activity | Increases total tau levels in cells overexpressing human tau protein | 115-7c | 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid | CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 | Dihydropyrimidine derivative | 45% | NA | NA | NA | 120 to 150 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000009 | 19793966 | Hsp70 | Hsc70/ DnaJ | Human | Cytosol and nucleus | Activation of ATPase activity | Increases total tau levels in cells overexpressing human tau protein | SW02 | ethyl 6-(4-bromophenyl)-3-(4-methoxy-4-oxobutyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCOC(=O)C1=C(N(C(=O)NC1C2=CC=C(C=C2)Br)CCCC(=O)OC)C | Dihydropyrimidine derivative | 45% | NA | NA | NA | 120 to 150 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000010 | 17904512 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 116-2F | methyl 4-(naphthalen-2-yl)-2-oxo-6-(phenoxymethyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate | COC(=O)C1=C(COC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 | Dihydropyrimidine derivative | NA | NA | NA | Between 120 and 200 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000011 | 17904512 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 116-4G | 6-{5-[(benzyloxy)carbonyl]-4-(4-cyclohexylphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1CCCCC1)C(=O)OCC1=CC=CC=C1 | Dihydropyrimidine derivative | NA | NA | NA | Between 120 and 201 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000012 | 17904512 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 116-7G | 5-[(6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}-N-hexylhexanamido)({[(1E)-butylidene]carbamoyl})methyl]-2-(carboxymethoxy)benzoic acid | CCCCCCN(C(C(=O)\N=C\CCC)C1=CC=C(OCC(O)=O)C(=C1)C(O)=O)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Dihydropyrimidine derivative | NA | NA | NA | Between 120 and 202 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000013 | 17904512 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 116-9e | 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 | Dihydropyrimidine derivative | NA | NA | NA | Between 120 and 203 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000014 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Az | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC | Imidazole derivative | 53.04% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000015 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-aminoadenosine analogue | 43.03% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000016 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 370 | (E)-N-(3-methyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | 50.42% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000017 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 371 | (E)-N-(3-methyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | 38.46% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000018 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 374 | (E)-N-(cyclopropyl(3-phenylthioureido)methyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C3CC3)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | 50.45% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000019 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 379 | (E)-N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | 44.12% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000020 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 380 | (E)-N-(3,3-dimethyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | 47.13% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000021 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 392 | (E)-N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C(C)(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | 50.5% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000022 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 394 | N-(3,3-dimethyl-1-(3-o-tolylthioureido)butyl)cinnamamide | Cc1ccccc1NC(=S)NC(CC(C)(C)C)NC(=O)C=Cc2ccccc2 | N,N'-disubstituted thiourea derivative | 40.95% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000023 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 397 | N-(cyclopropyl(3-o-tolylthioureido)methyl)cinnamamide | Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C3CC3 | N,N'-disubstituted thiourea derivative | 65.36% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000024 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 404 | (E)-N-(1-(3-cyclohexylthioureido)-3-methylbutyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)NC2CCCCC2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | 46.23% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000025 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 405 | (E)-N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | 35.78% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000026 | 27155465 | Hsp70 | DnaK/DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 407 | N-(1-(3-cyclohexylthioureido)-3-methylbutyl)cinnamamide | CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 | N,N'-disubstituted thiourea derivative | 58.37% (at 200 uM) | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000027 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 370 | (E)-N-(3-methyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 7.3 at 10 uM | Luminescence based viability assay |
| HSPMDB000028 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 371 | (E)-N-(3-methyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 9.2 at 10 uM | Luminescence based viability assay |
| HSPMDB000029 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 372 | (E)-N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C(C)(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 2.2 at 10 uM | Luminescence based viability assay |
| HSPMDB000030 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 373 | (E)-N-(2,2-dimethyl-1-(3-pyridin-3-ylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C(C)(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 10.3 at 10 uM | Luminescence based viability assay |
| HSPMDB000031 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 374 | (E)-N-(cyclopropyl(3-phenylthioureido)methyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C3CC3)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 12.2 at 10 uM | Luminescence based viability assay |
| HSPMDB000032 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 375 | (E)-N-(cyclopropyl(3-pyridin-3-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C3CC3)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 8.6 at 10 uM | Luminescence based viability assay |
| HSPMDB000033 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 376 | (E)-N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccn2)C3CC3)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 20.1 at 10 uM | Luminescence based viability assay |
| HSPMDB000034 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 378 | (E)-N-(3-methyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 24.9 at 10 uM | Luminescence based viability assay |
| HSPMDB000035 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 379 | (E)-N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 19 at 10 uM | Luminescence based viability assay |
| HSPMDB000036 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 380 | (E)-N-(3,3-dimethyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 22.1 at 10 uM | Luminescence based viability assay |
| HSPMDB000037 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 381 | (E)-N-(3,3-dimethyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 25.8 at 10 uM | Luminescence based viability assay |
| HSPMDB000038 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 382 | (E)-N-(2-methyl-1-(3-pyridin-2-ylureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccn2)C(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 12.4 at 10 uM | Luminescence based viability assay |
| HSPMDB000039 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 383 | (E)-N-(2-methyl-1-(3-phenylureido)propyl)-3-(3,4,5-trimethoxy-phenyl) acrylamide | COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccc2)C(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 4.8 at 10 uM | Luminescence based viability assay |
| HSPMDB000040 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 384 | N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)cinnamamide | O=C(NC(NC(=S)Nc1ccccn1)C2CC2)C=Cc3ccccc3 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 2.4 at 10 uM | Luminescence based viability assay |
| HSPMDB000041 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 386 | N-(3-methyl-1-(3-phenylthioureido)butyl)cinnamamide | CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 17.7 at 10 uM | Luminescence based viability assay |
| HSPMDB000042 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 387 | N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)cinnamamide | CC(C)(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 11.3 at 10 uM | Luminescence based viability assay |
| HSPMDB000043 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 388 | N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)cinnamamide | CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 9.6 at 10 uM | Luminescence based viability assay |
| HSPMDB000044 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 389 | N-(cyclopropyl(3-phenylthioureido)methyl)cinnamamide | O=C(NC(NC(=S)Nc1ccccc1)C2CC2)C=Cc3ccccc3 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 3.8 at 10 uM | Luminescence based viability assay |
| HSPMDB000045 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 390 | N-(2-methyl-1-(3-phenylthioureido)propyl)cinnamamide | CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 9.4 at 10 uM | Luminescence based viability assay |
| HSPMDB000046 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 391 | (E)-N-(3-methyl-1-(3-methylthioureido)butyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide | CNC(=S)NC(CC(C)C)NC(=O)\C=C\c1cc(OC)c(OC)c(OC)c1 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 10.5 at 10 uM | Luminescence based viability assay |
| HSPMDB000047 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 392 | (E)-N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C(C)(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 8.2 at 10 uM | Luminescence based viability assay |
| HSPMDB000048 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 393 | (E)-N-(cyclopropyl(3-o-tolylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C3CC3)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 44 at 10 uM | Luminescence based viability assay |
| HSPMDB000049 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 394 | N-(3,3-dimethyl-1-(3-o-tolylthioureido)butyl)cinnamamide | Cc1ccccc1NC(=S)NC(CC(C)(C)C)NC(=O)C=Cc2ccccc2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 18.2 at 10 uM | Luminescence based viability assay |
| HSPMDB000050 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 395 | N-(3-methyl-1-(3-o-tolylthioureido)butyl)cinnamamide | CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2C | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 9.8 at 10 uM | Luminescence based viability assay |
| HSPMDB000051 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 396 | N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)cinnamamide | Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C(C)(C)C | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 7 at 10 uM | Luminescence based viability assay |
| HSPMDB000052 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 397 | N-(cyclopropyl(3-o-tolylthioureido)methyl)cinnamamide | Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C3CC3 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 6 at 10 uM | Luminescence based viability assay |
| HSPMDB000053 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 402 | (E)-N-(1-(3-(4-methoxyphenyl)thioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1ccc(NC(=S)NC(NC(=O)\C=C\c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 11.5 at 10 uM | Luminescence based viability assay |
| HSPMDB000054 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 404 | (E)-N-(1-(3-cyclohexylthioureido)-3-methylbutyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)NC2CCCCC2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 16.5 at 10 uM | Luminescence based viability assay |
| HSPMDB000055 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 405 | (E)-N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 13.5 at 10 uM | Luminescence based viability assay |
| HSPMDB000056 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 406 | (E)-N-(1-(3-cyclohexylthioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 15.3 at 10 uM | Luminescence based viability assay |
| HSPMDB000057 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 407 | N-(1-(3-cyclohexylthioureido)-3-methylbutyl)cinnamamide | CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 13.5 at 10 uM | Luminescence based viability assay |
| HSPMDB000058 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 408 | N-(1-(3-cyclohexylthioureido)-2-methylpropyl)cinnamamide | CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 10.3 at 10 uM | Luminescence based viability assay |
| HSPMDB000059 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 409 | N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)cinnamamide | CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 13 at 10 uM | Luminescence based viability assay |
| HSPMDB000060 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 370 | (E)-N-(3-methyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 9.4 at 10 uM | Luminescence based viability assay |
| HSPMDB000061 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 371 | (E)-N-(3-methyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 10.5 at 10 uM | Luminescence based viability assay |
| HSPMDB000062 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 372 | (E)-N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C(C)(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 2.9 at 10 uM | Luminescence based viability assay |
| HSPMDB000063 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 373 | (E)-N-(2,2-dimethyl-1-(3-pyridin-3-ylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C(C)(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 16 at 10 uM | Luminescence based viability assay |
| HSPMDB000064 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 374 | (E)-N-(cyclopropyl(3-phenylthioureido)methyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2)C3CC3)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 13.7 at 10 uM | Luminescence based viability assay |
| HSPMDB000065 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 375 | (E)-N-(cyclopropyl(3-pyridin-3-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2cccnc2)C3CC3)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 12.3 at 10 uM | Luminescence based viability assay |
| HSPMDB000066 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 376 | (E)-N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccn2)C3CC3)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 17.4 at 10 uM | Luminescence based viability assay |
| HSPMDB000067 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 378 | (E)-N-(3-methyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 38.7 at 10 uM | Luminescence based viability assay |
| HSPMDB000068 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 379 | (E)-N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 40.9 at 10 uM | Luminescence based viability assay |
| HSPMDB000069 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 380 | (E)-N-(3,3-dimethyl-1-(3-pyridin-3-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2cccnc2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 19.3 at 10 uM | Luminescence based viability assay |
| HSPMDB000070 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 381 | (E)-N-(3,3-dimethyl-1-(3-pyridin-2-ylthioureido)butyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)(C)C)NC(=S)Nc2ccccn2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 31.5 at 10 uM | Luminescence based viability assay |
| HSPMDB000071 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 382 | (E)-N-(2-methyl-1-(3-pyridin-2-ylureido)propyl)-3-(3,4,5-trimethoxyphenyl) acrylamide | COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccn2)C(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 18.2 at 10 uM | Luminescence based viability assay |
| HSPMDB000072 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 383 | (E)-N-(2-methyl-1-(3-phenylureido)propyl)-3-(3,4,5-trimethoxy-phenyl) acrylamide | COc1cc(/C=C/C(=O)NC(NC(=O)Nc2ccccc2)C(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 11.4 at 10 uM | Luminescence based viability assay |
| HSPMDB000073 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 384 | N-(cyclopropyl(3-pyridin-2-ylthioureido)methyl)cinnamamide | O=C(NC(NC(=S)Nc1ccccn1)C2CC2)C=Cc3ccccc3 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 6 at 10 uM | Luminescence based viability assay |
| HSPMDB000074 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 386 | N-(3-methyl-1-(3-phenylthioureido)butyl)cinnamamide | CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 13.6 at 10 uM | Luminescence based viability assay |
| HSPMDB000075 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 387 | N-(3,3-dimethyl-1-(3-phenylthioureido)butyl)cinnamamide | CC(C)(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 34.6 at 10 uM | Luminescence based viability assay |
| HSPMDB000076 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 388 | N-(2,2-dimethyl-1-(3-phenylthioureido)propyl)cinnamamide | CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 11.4 at 10 uM | Luminescence based viability assay |
| HSPMDB000077 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 389 | N-(cyclopropyl(3-phenylthioureido)methyl)cinnamamide | O=C(NC(NC(=S)Nc1ccccc1)C2CC2)C=Cc3ccccc3 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 8.7 at 10 uM | Luminescence based viability assay |
| HSPMDB000078 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 390 | N-(2-methyl-1-(3-phenylthioureido)propyl)cinnamamide | CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 11.5 at 10 uM | Luminescence based viability assay |
| HSPMDB000079 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 391 | (E)-N-(3-methyl-1-(3-methylthioureido)butyl)-3-(3,4,5-trimethoxy-phenyl)acrylamide | CNC(=S)NC(CC(C)C)NC(=O)\C=C\c1cc(OC)c(OC)c(OC)c1 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 13 at 10 uM | Luminescence based viability assay |
| HSPMDB000080 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 392 | (E)-N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C(C)(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 9.9 at 10 uM | Luminescence based viability assay |
| HSPMDB000081 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 393 | (E)-N-(cyclopropyl(3-o-tolylthioureido)methyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)Nc2ccccc2C)C3CC3)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 6.8 at 10 uM | Luminescence based viability assay |
| HSPMDB000082 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 394 | N-(3,3-dimethyl-1-(3-o-tolylthioureido)butyl)cinnamamide | Cc1ccccc1NC(=S)NC(CC(C)(C)C)NC(=O)C=Cc2ccccc2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 18.9 at 10 uM | Luminescence based viability assay |
| HSPMDB000083 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 395 | N-(3-methyl-1-(3-o-tolylthioureido)butyl)cinnamamide | CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)Nc2ccccc2C | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 12.8 at 10 uM | Luminescence based viability assay |
| HSPMDB000084 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 396 | N-(2,2-dimethyl-1-(3-o-tolylthioureido)propyl)cinnamamide | Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C(C)(C)C | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 9.7 at 10 uM | Luminescence based viability assay |
| HSPMDB000085 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 397 | N-(cyclopropyl(3-o-tolylthioureido)methyl)cinnamamide | Cc1ccccc1NC(=S)NC(NC(=O)C=Cc2ccccc2)C3CC3 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 8.7 at 10 uM | Luminescence based viability assay |
| HSPMDB000086 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 402 | (E)-N-(1-(3-(4-methoxyphenyl)thioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1ccc(NC(=S)NC(NC(=O)\C=C\c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 15.4 at 10 uM | Luminescence based viability assay |
| HSPMDB000087 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 404 | (E)-N-(1-(3-cyclohexylthioureido)-3-methylbutyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(CC(C)C)NC(=S)NC2CCCCC2)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 38.8 at 10 uM | Luminescence based viability assay |
| HSPMDB000088 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 405 | (E)-N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 39.8 at 10 uM | Luminescence based viability assay |
| HSPMDB000089 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 406 | (E)-N-(1-(3-cyclohexylthioureido)-2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)acrylamide | COc1cc(/C=C/C(=O)NC(NC(=S)NC2CCCCC2)C(C)C)cc(OC)c1OC | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 22.6 at 10 uM | Luminescence based viability assay |
| HSPMDB000090 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 407 | N-(1-(3-cyclohexylthioureido)-3-methylbutyl)cinnamamide | CC(C)CC(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 19.8 at 10 uM | Luminescence based viability assay |
| HSPMDB000091 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 408 | N-(1-(3-cyclohexylthioureido)-2-methylpropyl)cinnamamide | CC(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 13.3 at 10 uM | Luminescence based viability assay |
| HSPMDB000092 | 27155465 | Hsp70 | Hsp70-2 | Human | Cytosol and cytoskeleton | NA | Antiproliferative activity | 409 | N-(1-(3-cyclohexylthioureido)-2,2-dimethylpropyl)cinnamamide | CC(C)(C)C(NC(=O)C=Cc1ccccc1)NC(=S)NC2CCCCC2 | N,N'-disubstituted thiourea derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | NA | 34.3 at 10 uM | Luminescence based viability assay |
| HSPMDB000093 | 29414793 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (protein-protein interaction) | NA | C | NA | NA | ChemDiv 100K diversity set library | NA | NA | NA | NA | <50 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000094 | 29414793 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (protein-protein interaction) | NA | F | 4-{2-[(3,5-dimethyl-1H-pyrazol-4-yl)amino]-1,3-thiazol-4-yl}benzene-1,2-diol | CC1=C(NC2=NC(=CS2)C2=CC=C(O)C(O)=C2)C(C)=NN1 | 2-aminothiazole derivative | NA | NA | NA | NA | <50 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000095 | 29414793 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (protein-protein interaction) | NA | I | NA | NA | ChemDiv 100K diversity set library | NA | NA | NA | NA | <50 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000096 | 29414793 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (protein-protein interaction) | NA | N | NA | NA | ChemDiv 100K diversity set library | NA | NA | NA | NA | <50 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000097 | 29414793 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (protein-protein interaction) | NA | R | N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 | 2-aminothiazole derivative | NA | NA | NA | NA | <50 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000098 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | Inhibition of ATPase activity (protein-protein interaction) | NA | C | NA | NA | ChemDiv 100K diversity set library | NA | NA | NA | NA | 26.2 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000099 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | Inhibition of ATPase activity (protein-protein interaction) | NA | F | 4-{2-[(3,5-dimethyl-1H-pyrazol-4-yl)amino]-1,3-thiazol-4-yl}benzene-1,2-diol | CC1=C(NC2=NC(=CS2)C2=CC=C(O)C(O)=C2)C(C)=NN1 | 2-aminothiazole derivative | NA | NA | NA | NA | 28.2 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000100 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | Inhibition of ATPase activity (protein-protein interaction) | NA | H | NA | NA | ChemDiv 100K diversity set library | NA | NA | NA | NA | 15.5 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000101 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | Inhibition of ATPase activity (protein-protein interaction) | NA | I | NA | NA | ChemDiv 100K diversity set library | NA | NA | NA | NA | 10.9 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000102 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | Inhibition of ATPase activity (protein-protein interaction) | NA | R | N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 | 2-aminothiazole derivative | NA | NA | NA | NA | 9.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000103 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | Inhibition of ATPase activity (protein-protein interaction) | NA | IT2-144 | N-(2,5-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(F)=CC=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | 6.9 | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000104 | 29414793 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (protein-protein interaction) | NA | IT2-149 | N-(2-fluoro-5-methylphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(C)=CC=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | >25 | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000105 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | Inhibition of ATPase activity (protein-protein interaction) | NA | IT2-151 | N-(5-bromo-2-fluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | 4.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000106 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | Inhibition of ATPase activity (protein-protein interaction) | NA | IT2-179 | N-(2,5-dibromophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2Br)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | 3.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000107 | 29414793 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (protein-protein interaction) | NA | IT2-158 | N-(2,3-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=CC(F)=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | >25 | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000108 | 29414793 | Hsp70 | Hsp72/-DnaJ2/BAG2 | Human | Cytosol and nucleus | Inhibition of ATPase activity (protein-protein interaction) | NA | IT2-159 | N-(2,4-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=C(F)C=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | >50 | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000109 | 29414793 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (protein-protein interaction) | NA | IT2-160 | N-(2,6-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=C(F)C=CC=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | >25 | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000110 | 29414793 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (protein-protein interaction) | NA | IT2-171 | N-benzyl-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NCC2=CC=CC=C2)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | >25 | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000111 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | Inhibition of ATPase activity (protein-protein interaction) | NA | IT2-70a | 4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(N)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | >50 | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000112 | 29414793 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (DnaJ stimulated) | NA | IT2-21c | 1-(3,4-dihydroxyphenyl)-2-(4-{[4-(3,4-dihydroxyphenyl)-1,3-thiazol-2-yl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)ethan-1-one | CC1=NN(CC(=O)C2=CC(O)=C(O)C=C2)C(C)=C1NC1=NC(=CS1)C1=CC(O)=C(O)C=C1 | IT2-21a derivative | 80% Inhibition at 10 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000113 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | R | N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 | 2-aminothiazoles derivative | NA | NA | NA | NA | 5.8 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000114 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | IT2-144 | N-(2,5-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(F)=CC=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | 2.7 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000115 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | IT2-151 | N-(5-bromo-2-fluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | 2.9 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000116 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | IT2-179 | N-(2,5-dibromophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2Br)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | 3.1 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000117 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | IT2-159 | N-(2,4-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=C(F)C=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | 8.5 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000118 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | IT2-70a | 4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(N)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | > 50 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000119 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | R | N-(5-chloro-2-methoxyphenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | COC1=CC=C(Cl)C=C1NC1=NC(=CS1)C1=C(C)N=C2C=CC=CN12 | 2-aminothiazoles derivative | NA | NA | NA | NA | 5.3 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000120 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | IT2-144 | N-(2,5-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(F)=CC=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | > 50 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000121 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | IT2-151 | N-(5-bromo-2-fluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | 9.3 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000122 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | IT2-179 | N-(2,5-dibromophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC(Br)=CC=C2Br)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | > 50 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000123 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | IT2-159 | N-(2,4-difluorophenyl)-4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(NC2=CC=C(F)C=C2F)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | 5.4 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000124 | 29414793 | Hsp70 | Hsp72/DnaJ2/BAG2 | Human | Cytosol and nucleus | NA | Antiproliferative activity | IT2-70a | 4-{2-methylimidazo[1,2-a]pyridin-3-yl}-1,3-thiazol-2-amine | CC1=C(N2C=CC=CC2=N1)C1=CSC(N)=N1 | 2-aminothiazoles derivative | NA | NA | NA | NA | > 50 | NA | NA | NA | NA | NA | NA | MTT viability assay |
| HSPMDB000125 | 18191466 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of chaperone activity | NA | 116-5c | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)[4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl]methyl](2-phenylethyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCC1=CC=CC=C1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(OCC(=O)OC)C(=C1)C(=O)OC | Dihydropyrimidine derivative | NA | NA | NA | NA | 3.2 | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000126 | 18191466 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of chaperone activity | NA | 115-3b | 2-[(2-{5-[(benzyloxy)carbonyl]-1-(3-carboxypropyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl}phenoxy)sulfonyl]-N-hydroxy-N-oxoanilinium | CC1=C(C(NC(=O)N1CCCC(O)=O)C1=CC=CC=C1OS(=O)(=O)C1=CC=CC=C1[N+](O)=O)C(=O)OCC1=CC=CC=C1 | Dihydropyrimidine derivative | NA | NA | NA | NA | 3.5 | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000127 | 18191466 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of chaperone activity | NA | 116-4d | N-hydroxy-4-[5-(methoxycarbonyl)-2-oxo-6-(2-phenylethyl)-1,2,3,4-tetrahydropyrimidin-4-yl]-N-oxoanilinium | COC(=O)C1=C(CCC2=CC=CC=C2)NC(=O)NC1C1=CC=C(C=C1)[N+](O)=O | Dihydropyrimidine derivative | NA | NA | NA | NA | 8.8 | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000128 | 18191466 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of chaperone activity | NA | 116-10d | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)[4-hydroxy-3-(methoxycarbonyl)phenyl]methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)C1=CC=C(O)C(=C1)C(=O)OC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Dihydropyrimidine derivative | NA | NA | NA | NA | 9 | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000129 | 18191466 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of chaperone activity | NA | SW03 | 3-[(3R)-3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-methylhexanamido]-3-phenylpropanamido]propanoic acid | CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CC(C)C)CC(=O)N[C@H](CC(=O)NCCC(O)=O)C2=CC=CC=C2)C(=O)NC1C1=CC=C(Br)C=C1 | Dihydropyrimidine derivative | NA | NA | NA | NA | 11 | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000130 | 18191466 | Hsp70 | DnaK/DnaJ/GrpE | Bacteria | Cytosol and membrane | Inhibition of chaperone activity | NA | 116-8e | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)(hexyl)carbamoyl]pentyl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Dihydropyrimidine derivative | NA | NA | NA | NA | 30.4 | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000131 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 625194 | NA | NA | Dihydropyrimidine derivative | Fold change 1 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000132 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 625195 | NA | NA | Dihydropyrimidine derivative | Fold change 3 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000133 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 625512 | NA | NA | Dihydropyrimidine derivative | Fold change 1.2 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000134 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 625513 | NA | NA | Dihydropyrimidine derivative | Fold change 1.1 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000135 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | ML2-193 | NA | NA | Dihydropyrimidine derivative | Fold change 1.6 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000136 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | ML2-194 | NA | NA | Dihydropyrimidine derivative | Fold change 1.3 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000137 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | ML2-214 | NA | NA | Dihydropyrimidine derivative | Fold change -1.1 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000138 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | ML2-215 | NA | NA | Dihydropyrimidine derivative | Fold change 1.2 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000139 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-38 | NA | NA | Dihydropyrimidine derivative | Fold change 1.8 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000140 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-40 | NA | NA | Dihydropyrimidine derivative | Fold change 1.8 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000141 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-53 | NA | NA | Dihydropyrimidine derivative | Fold change 1.9 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000142 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-55 | NA | NA | Dihydropyrimidine derivative | Fold change -1.5 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000143 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-87 | NA | NA | Dihydropyrimidine derivative | Fold change 1.9 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000144 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-88 | NA | NA | Dihydropyrimidine derivative | Fold change 1.5 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000145 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-90 | NA | NA | Dihydropyrimidine derivative | Fold change 2 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000146 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-91 | NA | NA | Dihydropyrimidine derivative | Fold change 1.8 (at 0.1 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000147 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | NSC-630668-R/1 | 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate | CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCCCCCOC(=O)NCCCCCCNC(=O)OCCCCCCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC | Dihydropyrimidine derivative | Fold change 5.8 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000148 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 624392 | ethyl N-[1-[2-[6-[[2-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]ethyl-(2-hydroxyethyl)carbamoyl]amino]hexylcarbamoyl-(2-hydroxyethyl)amino]ethyl]-2,4-dioxopyrimidine-5-carbonyl]carbamate | CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCN(CCO)C(=O)NCCCCCCNC(=O)N(CCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC)CCO | Dihydropyrimidine derivative | Fold change -1.3 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000149 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 642393 | NA | NA | Dihydropyrimidine derivative | Fold change -1.7 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000150 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 624903 | NA | NA | Dihydropyrimidine derivative | Fold change -2.2 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000151 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 624904 | NA | NA | Dihydropyrimidine derivative | Fold change -1.4 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000152 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 624905 | NA | NA | Dihydropyrimidine derivative | Fold change 1.2 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000153 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 624906 | NA | NA | Dihydropyrimidine derivative | Fold change -1.8 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000154 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 624907 | NA | NA | Dihydropyrimidine derivative | Fold change 1.2 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000155 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 624908 | NA | NA | Dihydropyrimidine derivative | Fold change -1.1 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000156 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 625194 | NA | NA | Dihydropyrimidine derivative | Fold change 1.8 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000157 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 625195 | NA | NA | Dihydropyrimidine derivative | Fold change 1.7 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000158 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 625512 | NA | NA | Dihydropyrimidine derivative | Fold change 3.1 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000159 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 625513 | NA | NA | Dihydropyrimidine derivative | Fold change 2 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000160 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 632006 | NA | NA | Dihydropyrimidine derivative | Fold change 1.4 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000161 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 655302 | NA | NA | Dihydropyrimidine derivative | Fold change 1.9 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000162 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | aad9 | NA | NA | Dihydropyrimidine derivative | Fold change -1.7 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000163 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | ML2-193 | NA | NA | Dihydropyrimidine derivative | Fold change 3.1 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000164 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | ML2-194 | NA | NA | Dihydropyrimidine derivative | Fold change 2.1 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000165 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | ML2-214 | NA | NA | Dihydropyrimidine derivative | Fold change 1.7 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000166 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | ML2-215 | NA | NA | Dihydropyrimidine derivative | Fold change 2.2 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000167 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-38 | NA | NA | Dihydropyrimidine derivative | Fold change 3.1 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000168 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-39 | NA | NA | Dihydropyrimidine derivative | Fold change 1 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000169 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-40 | NA | NA | Dihydropyrimidine derivative | Fold change 2.7 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000170 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-51 | NA | NA | Dihydropyrimidine derivative | Fold change -1.2 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000171 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-53 | NA | NA | Dihydropyrimidine derivative | Fold change 2.5 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000172 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-54 | NA | NA | Dihydropyrimidine derivative | Fold change 1.1 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000173 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-55 | NA | NA | Dihydropyrimidine derivative | Fold change 1.4 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000174 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-87 | NA | NA | Dihydropyrimidine derivative | Fold change 2.3 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000175 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-88 | NA | NA | Dihydropyrimidine derivative | Fold change 1.3 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000176 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-90 | NA | NA | Dihydropyrimidine derivative | Fold change 5.2 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000177 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-91 | NA | NA | Dihydropyrimidine derivative | Fold change 2.9 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000178 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-101 | Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 | Dihydropyrimidine derivative | Fold change 1 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000179 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 624392 | ethyl N-[1-[2-[6-[[2-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]ethyl-(2-hydroxyethyl)carbamoyl]amino]hexylcarbamoyl-(2-hydroxyethyl)amino]ethyl]-2,4-dioxopyrimidine-5-carbonyl]carbamate | CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCN(CCO)C(=O)NCCCCCCNC(=O)N(CCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC)CCO | Dihydropyrimidine derivative | Fold change -1.4 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000180 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 624906 | NA | NA | Dihydropyrimidine derivative | Fold change -1.1 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000181 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 625194 | NA | NA | Dihydropyrimidine derivative | Fold change 1.4 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000182 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 625195 | NA | NA | Dihydropyrimidine derivative | Fold change1.3 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000183 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 625512 | NA | NA | Dihydropyrimidine derivative | Fold change 3 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000184 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 625513 | NA | NA | Dihydropyrimidine derivative | Fold change 2.5 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000185 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | 632006 | NA | NA | Dihydropyrimidine derivative | Fold change 2 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000186 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | 655302 | NA | NA | Dihydropyrimidine derivative | Fold change -1.3 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000187 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | ML2-193 | NA | NA | Dihydropyrimidine derivative | Fold change 2.3 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000188 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | ML2-194 | NA | NA | Dihydropyrimidine derivative | Fold change 1.4 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000189 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | ML2-214 | NA | NA | Dihydropyrimidine derivative | Fold change 1.3 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000190 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | ML2-215 | NA | NA | Dihydropyrimidine derivative | Fold change 2.1 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000191 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-38 | NA | NA | Dihydropyrimidine derivative | Fold change 2 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000192 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-39 | NA | NA | Dihydropyrimidine derivative | Foldc hange -1.4 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000193 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-40 | NA | NA | Dihydropyrimidine derivative | Fold change 3 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000194 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-51 | NA | NA | Dihydropyrimidine derivative | Fold change -1.3 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000195 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-53 | NA | NA | Dihydropyrimidine derivative | Fold change 4.6 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000196 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-54 | NA | NA | Dihydropyrimidine derivative | Fold change 1.3 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000197 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-55 | NA | NA | Dihydropyrimidine derivative | Fold change 2.8 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000198 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-87 | NA | NA | Dihydropyrimidine derivative | Fold change 2.6 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000199 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-88 | NA | NA | Dihydropyrimidine derivative | Fold change 2.4 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000200 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-90 | NA | NA | Dihydropyrimidine derivative | Fold change 6.7 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000201 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-91 | NA | NA | Dihydropyrimidine derivative | Fold change 5 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000202 | 15448148 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity (endogenous) | NA | MAL3-101 | Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 | Dihydropyrimidine derivative | Fold change 1.2 (at 0.6 mM) | NA | NA | NA | NA | NA | NA | NA | Interface between Hsp70 and Hsp40 | ATPase assay | NA | NA |
| HSPMDB000203 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | NSC-630668-R/1 | 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate | CCOC(=O)NC(=O)C1=CN(C(=O)NC1=O)CCCCCCOC(=O)NCCCCCCNC(=O)OCCCCCCN2C=C(C(=O)NC2=O)C(=O)NC(=O)OCC | Dihydropyrimidine derivative | Fold change -1.5 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000204 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Activation of ATPase activity (TAg stimulated) | NA | MAL3-38 | NA | NA | Dihydropyrimidine derivative | Fold change 2 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000205 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL3-39 | NA | NA | Dihydropyrimidine derivative | Fold change -2.8 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000206 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Activation of ATPase activity (TAg stimulated) | NA | MAL3-40 | NA | NA | Dihydropyrimidine derivative | Fold change 1.5 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000207 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL3-51 | NA | NA | Dihydropyrimidine derivative | Fold change -1.1 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000208 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Activation of ATPase activity (TAg stimulated) | NA | MAL3-53 | NA | NA | Dihydropyrimidine derivative | Fold change 1.2 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000209 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL3-54 | NA | NA | Dihydropyrimidine derivative | Fold change -5.1(at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000210 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL3-55 | NA | NA | Dihydropyrimidine derivative | Fold change -1.8 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000211 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Activation of ATPase activity (TAg stimulated) | NA | MAL3-87 | NA | NA | Dihydropyrimidine derivative | Fold change 1.8 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000212 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Activation of ATPase activity (TAg stimulated) | NA | MAL3-88 | NA | NA | Dihydropyrimidine derivative | Fold change 1.5 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000213 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Activation of ATPase activity (TAg stimulated) | NA | MAL3-90 | NA | NA | Dihydropyrimidine derivative | Fold change 4.2 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000214 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Activation of ATPase activity (TAg stimulated) | NA | MAL3-91 | NA | NA | Dihydropyrimidine derivative | Fold change 1.4 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000215 | 15448148 | Hsp70 | Ssa1p and TAg /ydj1P | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL3-101 | Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 | Dihydropyrimidine derivative | Fold change -4 (at 0.3 mM) | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000216 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-101 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 1.7 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000217 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL3-51 | N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide | CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000218 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT002272 | 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(2-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2c3ccccc3)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000219 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003034 | 6-(6-cyclohexyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CCCCC2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000220 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003036 | 6-[6-(4-tert-butylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(C)(C)C)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000221 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003038 | 6-(6-cyclopropyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CC2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000222 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003116 | 6-[6-(4-cyclohexylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C3CCCCC3)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000223 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL1-274 | 6-[6-(4-chlorophenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(Cl)cc2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1.3 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000224 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL2-06A | 6-(4-methyl-6-naphthalen-2-yl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc3ccccc3c2)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000225 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL2-10A | 6-(4-methyl-2-oxo-6-phenyl-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1.5 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000226 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL2-116-17 | 6-[4-methyl-6-(3-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2cccc(c2)[N+]([O-])=O)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change -1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000227 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL2-116-20 | 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(F)(F)F)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000228 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL2-11B | 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)c3ccccc3)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000229 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | MAL2-13 | 6-[4-methyl-6-(4-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)[N+]([O-])=O)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000230 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003042 | benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | COC(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 2.6 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000231 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003044 | benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate | COC(=O)CCCCCN1C(=O)NC(c2ccccc2)C(=C1C)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 2.3 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000232 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003046 | benzyl 6-cyclopropyl-3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | COC(=O)CCCCCN1C(=O)NC(C2CC2)C(=C1C)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1.9 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000233 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003082 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(F)(F)F)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000234 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003084 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-tert-butylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(C)(C)C)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000235 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003086 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(3-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3cccc(c3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000236 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003088 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000237 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003090 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-chlorophenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(Cl)cc3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1.3 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000238 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003092 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000239 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003094 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-naphthalen-2-yl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc4ccccc4c3)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000240 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003096 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(2-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change -1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000241 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003100 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclohexyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CCCCC3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000242 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003132 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000243 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003134 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-cyclohexylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C4CCCCC4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 2.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000244 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT002218 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-phenylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 3.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000245 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT002220 | benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxyphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(O)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 11.8 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000246 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT002222 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(cc1)c2ccccc2)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6 | Dihydropyrimidine derivative | Fold change 9.9 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000247 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT002260 | benzyl 3-[6-[[2-(butylamino)-1-(3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1cccc(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 3.7 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000248 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT002262 | benzyl 3-[6-[[1-(butylamino)-1-oxopropan-2-yl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1.6 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000249 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT002264 | benzyl 3-[6-[[2-(butylamino)-1-cyclohexyl-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 3.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000250 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003058 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-pyridin-2-ylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 4.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000251 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003112 | benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxy-3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(O)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 19.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000252 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003114 | benzyl 3-[6-[[2-(butylamino)-1-[4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000253 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT002286 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(cyclohexen-1-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCC1=CCCCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | Fold change 6.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000254 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003052 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC | Dihydropyrimidine derivative | Fold change 1.5 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000255 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003102 | benzyl 3-[6-[benzyl-[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(Cc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | Fold change 1.5 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000256 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003104 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-phenylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | Fold change 12.3 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000257 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003106 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(pyridin-2-ylmethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(Cc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | Fold change 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000258 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003108 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-pyridin-2-ylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | Fold change -1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000259 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003110 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCc1c[nH]c2ccccc12)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6)c7ccc(OCC(=O)OC)c(c7)C(=O)OC | Dihydropyrimidine derivative | Fold change 10.3 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000260 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003020 | 5-[2-(butylamino)-1-[hexyl-[6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoyl]amino]-2-oxoethyl]-2-(carboxymethoxy)benzoic acid | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(O)=O)c(c1)C(O)=O)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000261 | 18164205 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | DMT003024 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-(2-morpholin-4-ylethyl)amino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4)c5ccc(cc5)c6ccccc6 | Dihydropyrimidine derivative | Fold change 2.3 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000262 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL3-101 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change -2.0 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000263 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL3-51 | N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide | CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 | Dihydropyrimidine derivative | Fold change -2.0 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000264 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT002272 | 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(2-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2c3ccccc3)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -5.0 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000265 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003034 | 6-(6-cyclohexyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CCCCC2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1.5 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000266 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003036 | 6-[6-(4-tert-butylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(C)(C)C)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change -3.5 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000267 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003038 | 6-(6-cyclopropyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CC2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000268 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003116 | 6-[6-(4-cyclohexylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C3CCCCC3)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -2.4 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000269 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL1-274 | 6-[6-(4-chlorophenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(Cl)cc2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change -1.6 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000270 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL2-06A | 6-(4-methyl-6-naphthalen-2-yl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc3ccccc3c2)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -1.4 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000271 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL2-10A | 6-(4-methyl-2-oxo-6-phenyl-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change -1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000272 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL2-116-17 | 6-[4-methyl-6-(3-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2cccc(c2)[N+]([O-])=O)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000273 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL2-116-20 | 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(F)(F)F)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000274 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL2-11B | 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)c3ccccc3)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -3.5 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000275 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | MAL2-13 | 6-[4-methyl-6-(4-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)[N+]([O-])=O)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000276 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003042 | benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | COC(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -1.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000277 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003044 | benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate | COC(=O)CCCCCN1C(=O)NC(c2ccccc2)C(=C1C)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change -1.7 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000278 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003046 | benzyl 6-cyclopropyl-3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | COC(=O)CCCCCN1C(=O)NC(C2CC2)C(=C1C)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | Fold change 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000279 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003082 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(F)(F)F)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -4.8 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000280 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003084 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-tert-butylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(C)(C)C)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -5.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000281 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003086 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(3-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3cccc(c3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -1.5 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000282 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003088 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000283 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003090 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-chlorophenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(Cl)cc3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -5.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000284 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003092 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000285 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003094 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-naphthalen-2-yl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc4ccccc4c3)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change -1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000286 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003096 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(2-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change -4.0 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000287 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003100 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclohexyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CCCCC3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -2.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000288 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003132 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change -2.6 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000289 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003134 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-cyclohexylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C4CCCCC4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change -1.6 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000290 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT002218 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-phenylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000291 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT002220 | benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxyphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(O)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 9.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000292 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT002222 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(cc1)c2ccccc2)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6 | Dihydropyrimidine derivative | Fold change 6 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000293 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT002260 | benzyl 3-[6-[[2-(butylamino)-1-(3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1cccc(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change -2.0 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000294 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT002262 | benzyl 3-[6-[[1-(butylamino)-1-oxopropan-2-yl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | Fold change 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000295 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT002264 | benzyl 3-[6-[[2-(butylamino)-1-cyclohexyl-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000296 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003058 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-pyridin-2-ylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 5.5 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000297 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003112 | benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxy-3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(O)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 2.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000298 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003114 | benzyl 3-[6-[[2-(butylamino)-1-[4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change 1.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000299 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT002286 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(cyclohexen-1-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCC1=CCCCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | Fold change -1.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000300 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003052 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC | Dihydropyrimidine derivative | Fold change -1.8 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000301 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003102 | benzyl 3-[6-[benzyl-[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(Cc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | Fold change -1.9 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000302 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003104 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-phenylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | Fold change 1.3 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000303 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003106 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(pyridin-2-ylmethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(Cc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | Fold change -1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000304 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003108 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-pyridin-2-ylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | Fold change -1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000305 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003110 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCc1c[nH]c2ccccc12)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6)c7ccc(OCC(=O)OC)c(c7)C(=O)OC | Dihydropyrimidine derivative | Fold change -1.3 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000306 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003020 | 5-[2-(butylamino)-1-[hexyl-[6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoyl]amino]-2-oxoethyl]-2-(carboxymethoxy)benzoic acid | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(O)=O)c(c1)C(O)=O)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | Fold change -2.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000307 | 18164205 | Hsp70 | Ssa1p and TAg | Yeast | Cytosol | Inhibition of ATPase activity (TAg stimulated) | NA | DMT003024 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-(2-morpholin-4-ylethyl)amino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4)c5ccc(cc5)c6ccccc6 | Dihydropyrimidine derivative | Fold change -5.0 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000308 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL3-101 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 27 | NA | NA | NA | MTT viability assay |
| HSPMDB000309 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL3-51 | N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide | CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000310 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT002272 | 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(2-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2c3ccccc3)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000311 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003034 | 6-(6-cyclohexyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CCCCC2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000312 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003036 | 6-[6-(4-tert-butylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(C)(C)C)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000313 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003038 | 6-(6-cyclopropyl-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C2CC2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000314 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003116 | 6-[6-(4-cyclohexylphenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C3CCCCC3)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000315 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL1-274 | 6-[6-(4-chlorophenyl)-4-methyl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(Cl)cc2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000316 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL2-06A | 6-(4-methyl-6-naphthalen-2-yl-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc3ccccc3c2)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000317 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL2-10A | 6-(4-methyl-2-oxo-6-phenyl-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl)hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccccc2)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000318 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL2-116-17 | 6-[4-methyl-6-(3-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2cccc(c2)[N+]([O-])=O)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000319 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL2-116-20 | 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)C(F)(F)F)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000320 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL2-11B | 6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)c3ccccc3)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000321 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL2-13 | 6-[4-methyl-6-(4-nitrophenyl)-2-oxo-5-phenylmethoxycarbonyl-1,6-dihydropyrimidin-3-yl]hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)c2ccc(cc2)[N+]([O-])=O)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000322 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003042 | benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | COC(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000323 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003044 | benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate | COC(=O)CCCCCN1C(=O)NC(c2ccccc2)C(=C1C)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000324 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003046 | benzyl 6-cyclopropyl-3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | COC(=O)CCCCCN1C(=O)NC(C2CC2)C(=C1C)C(=O)OCc3ccccc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000325 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003082 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-[4-(trifluoromethyl)phenyl]-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(F)(F)F)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000326 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003084 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-tert-butylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C(C)(C)C)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 29 | NA | NA | NA | MTT viability assay |
| HSPMDB000327 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003086 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(3-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3cccc(c3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 6 | NA | NA | NA | MTT viability assay |
| HSPMDB000328 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003088 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 6.5 | NA | NA | NA | MTT viability assay |
| HSPMDB000329 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003090 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-chlorophenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(Cl)cc3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 16 | NA | NA | NA | MTT viability assay |
| HSPMDB000330 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003092 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 6.9 | NA | NA | NA | MTT viability assay |
| HSPMDB000331 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003094 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-6-naphthalen-2-yl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc4ccccc4c3)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 10 | NA | NA | NA | MTT viability assay |
| HSPMDB000332 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003096 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(2-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 17 | NA | NA | NA | MTT viability assay |
| HSPMDB000333 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003100 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclohexyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CCCCC3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 6.3 | NA | NA | NA | MTT viability assay |
| HSPMDB000334 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003132 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 6.2 | NA | NA | NA | MTT viability assay |
| HSPMDB000335 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003134 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-(4-cyclohexylphenyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)C4CCCCC4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 42 | NA | NA | NA | MTT viability assay |
| HSPMDB000336 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT002218 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-phenylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000337 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT002220 | benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxyphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(O)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000338 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT002222 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(cc1)c2ccccc2)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000339 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT002260 | benzyl 3-[6-[[2-(butylamino)-1-(3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1cccc(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000340 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT002262 | benzyl 3-[6-[[1-(butylamino)-1-oxopropan-2-yl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000341 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT002264 | benzyl 3-[6-[[2-(butylamino)-1-cyclohexyl-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000342 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003058 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-pyridin-2-ylethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000343 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003112 | benzyl 3-[6-[[2-(butylamino)-1-(4-hydroxy-3-methoxycarbonylphenyl)-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(O)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000344 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003114 | benzyl 3-[6-[[2-(butylamino)-1-[4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)cc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 48 | NA | NA | NA | MTT viability assay |
| HSPMDB000345 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT002286 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(cyclohexen-1-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCC1=CCCCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 39 | NA | NA | NA | MTT viability assay |
| HSPMDB000346 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003052 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 8.8 | NA | NA | NA | MTT viability assay |
| HSPMDB000347 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003102 | benzyl 3-[6-[benzyl-[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(Cc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 14 | NA | NA | NA | MTT viability assay |
| HSPMDB000348 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003104 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-phenylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCc1ccccc1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 32 | NA | NA | NA | MTT viability assay |
| HSPMDB000349 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003106 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(pyridin-2-ylmethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(Cc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 7.1 | NA | NA | NA | MTT viability assay |
| HSPMDB000350 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003108 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-pyridin-2-ylethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCc1ccccn1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5)c6ccc(OCC(=O)OC)c(c6)C(=O)OC | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 7.5 | NA | NA | NA | MTT viability assay |
| HSPMDB000351 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003110 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-[2-(1H-indol-3-yl)ethyl]amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCc1c[nH]c2ccccc12)C(=O)CCCCCN3C(=O)NC(c4ccc(cc4)c5ccccc5)C(=C3C)C(=O)OCc6ccccc6)c7ccc(OCC(=O)OC)c(c7)C(=O)OC | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000352 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003020 | 5-[2-(butylamino)-1-[hexyl-[6-[4-methyl-2-oxo-5-phenylmethoxycarbonyl-6-(4-phenylphenyl)-1,6-dihydropyrimidin-3-yl]hexanoyl]amino]-2-oxoethyl]-2-(carboxymethoxy)benzoic acid | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(O)=O)c(c1)C(O)=O)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000353 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003024 | benzyl 3-[6-[[2-(butylamino)-2-oxo-1-(4-phenylphenyl)ethyl]-(2-morpholin-4-ylethyl)amino]-6-oxohexyl]-4-methyl-6-(4-nitrophenyl)-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)[N+]([O-])=O)C(=C2C)C(=O)OCc4ccccc4)c5ccc(cc5)c6ccccc6 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000354 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL3-101 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 14.7 | NA | NA | NA | MTT viability assay |
| HSPMDB000355 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL3-51 | N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide | CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000356 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003088 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 2.4 | NA | NA | NA | MTT viability assay |
| HSPMDB000357 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003132 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 6.3 | NA | NA | NA | MTT viability assay |
| HSPMDB000358 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003052 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 7.8 | NA | NA | NA | MTT viability assay |
| HSPMDB000359 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL3-101 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccc(cc3)c4ccccc4)C(=C2C)C(=O)OCc5ccccc5 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000360 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | MAL3-51 | N-[4-[[2-(tert-butylamino)-1-(4-iodophenyl)-2-oxoethyl]-(2-morpholin-4-ylethyl)amino]-4-oxobutyl]benzamide | CC(C)(C)NC(=O)C(N(CCN1CCOCC1)C(=O)CCCNC(=O)c2ccccc2)c3ccc(I)cc3 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | >50 | NA | NA | NA | MTT viability assay |
| HSPMDB000361 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003088 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(c3ccccc3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 4.8 | NA | NA | NA | MTT viability assay |
| HSPMDB000362 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003132 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-6-cyclopropyl-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCCCCCN(C(C(=O)NCCCC)c1ccc(OCC(=O)OC)c(c1)C(=O)OC)C(=O)CCCCCN2C(=O)NC(C3CC3)C(=C2C)C(=O)OCc4ccccc4 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 5.3 | NA | NA | NA | MTT viability assay |
| HSPMDB000363 | 18164205 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | NA | Antiproliferative activity | DMT003052 | benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-(2-methoxyethyl)amino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCOC)C(=O)CCCCCN1C(=O)NC(c2ccc(cc2)c3ccccc3)C(=C1C)C(=O)OCc4ccccc4)c5ccc(OCC(=O)OC)c(c5)C(=O)OC | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | 3.1 | NA | NA | NA | MTT viability assay |
| HSPMDB000364 | 21426241 | Hsp70 | PfHsp70-1 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of protein aggregation activity | NA | Malonganenone A | 3-methyl-7-[(2E,6E,11Z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]-6,7-dihydro-3H-purin-6-one | CC(C)CC(=O)\C=C(\C)CCC\C(C)=C\CC\C(C)=C\CN1C=NC2=C1C(=O)N=CN2C | Marine tetraprenylated alkaloid | >90% at 300 uM | NA | NA | NA | NA | NA | NA | NA | NA | Substrate aggregation suppression assay | NA | NA |
| HSPMDB000365 | 21426241 | Hsp70 | PfHsp70-1 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of protein aggregation activity | NA | Malonganenone B | N-methyl-4-(N-methylformamido)-1-[(2E,6E,11Z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]-1H-imidazole-5-carboxamide | [H]C(=O)N(C)C1=C(N(C\C=C(/C)CC\C=C(/C)CCC\C(C)=C/C(=O)CC(C)C)C=N1)C(=O)NC | Marine tetraprenylated alkaloid | >90% at 300 uM | NA | NA | NA | NA | NA | NA | NA | NA | Substrate aggregation suppression assay | NA | NA |
| HSPMDB000366 | 21426241 | Hsp70 | PfHsp70-1 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of protein aggregation activity | NA | Malonganenone C | N-[(2E,6E,11Z)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]formamide | [H]C(=O)NC\C=C(/C)CC\C=C(/C)CCC\C(C)=C/C(=O)CC(C)C | Marine tetraprenylated alkaloid | >90% at 300 uM | NA | NA | NA | NA | NA | NA | NA | NA | Substrate aggregation suppression assay | NA | NA |
| HSPMDB000367 | 21426241 | Hsp70 | PfHsp70-1 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of protein aggregation activity | NA | Lapachol | 2-hydroxy-3-(3-methylbut-2-en-1-yl)-1,4-dihydronaphthalene-1,4-dione | CC(C)=CCC1=C(O)C(=O)C2=C(C=CC=C2)C1=O | 1,4 naphthoquinone | >90% at 300 uM | NA | NA | NA | NA | NA | NA | NA | NA | Substrate aggregation suppression assay | NA | NA |
| HSPMDB000368 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Almond | NA | NA | Flavonoid | 95% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000369 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Vanilla | NA | NA | Flavonoid | 92% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000370 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Chili Powder | NA | NA | Flavonoid | 101% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000371 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Cloves | NA | NA | Flavonoid | 59% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000372 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Chives | NA | NA | Flavonoid | 88% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000373 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Chocolate | NA | NA | Flavonoid | 96% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000374 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Cilantro (leaves) | NA | NA | Flavonoid | 91% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000375 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Cinnamon | NA | NA | Flavonoid | 46% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000376 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Coriander | NA | NA | Flavonoid | 98% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000377 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Cumin | NA | NA | Flavonoid | 94% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000378 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Allspice | NA | NA | Flavonoid | 53% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000379 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Dill weed | NA | NA | Flavonoid | 94% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000380 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Fennel seed | NA | NA | Flavonoid | 93% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000381 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Fenugreek seed | NA | NA | Flavonoid | 98% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000382 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Galangal | NA | NA | Flavonoid | 86% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000383 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Ginger | NA | NA | Flavonoid | 94% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000384 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Lemon (peel) | NA | NA | Flavonoid | 99% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000385 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Mustard | NA | NA | Flavonoid | 84% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000386 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Nutmeg | NA | NA | Flavonoid | 89% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000387 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Orange (peel) | NA | NA | Flavonoid | 96% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000388 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Black Tea | NA | NA | Flavonoid | 55% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000389 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Paprika | NA | NA | Flavonoid | 104% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000390 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Parsley flakes | NA | NA | Flavonoid | 96% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000391 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Pepper (cayenne) | NA | NA | Flavonoid | 101% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000392 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Poppy seed | NA | NA | Flavonoid | 98% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000393 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Red Pepper | NA | NA | Flavonoid | 99% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000394 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | White Tea | NA | NA | Flavonoid | 67% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000395 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Turmeric Root | NA | NA | Flavonoid | 101% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000396 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Anise Seeds | NA | NA | Flavonoid | 96% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000397 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Vanilla Bean | NA | NA | Flavonoid | 97% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000398 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | White pepper | NA | NA | Flavonoid | 89% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000399 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Aloe | NA | NA | Flavonoid | 90% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000400 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Basil leaves | NA | NA | Flavonoid | 94% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000401 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Cocoa | NA | NA | Flavonoid | 68% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000402 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Cardamom | NA | NA | Flavonoid | 102% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000403 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Chili powder | NA | NA | Flavonoid | 96% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000404 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Quercetin | 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one | OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1 | Flavonoid | 67% at 200 uM | NA | NA | 24.9 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000405 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | QTE | 2-(3,4-dimethoxyphenyl)-3-hydroxy-5,7-dimethoxy-4H-chromen-4-one | COC1=CC2=C(C(=O)C(O)=C(O2)C2=CC=C(OC)C(OC)=C2)C(OC)=C1 | Flavonoid | NA | NA | NA | >200 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000406 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Rhamnetin | 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-methoxy-4H-chromen-4-one | COC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1 | Flavonoid | 13% at 200 uM | NA | NA | >200 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000407 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (DnaJ stimulated) | NA | Myricetin | 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one | OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC(O)=C(O)C(O)=C1 | Flavonoid | 75% at 200 uM | NA | NA | 14.5 | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000408 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Kaempferol | 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one | OC1=CC=C(C=C1)C1=C(O)C(=O)C2=C(O1)C=C(O)C=C2O | Flavonoid | 15% at 200 uM | NA | NA | >200 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000409 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Morin | 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one | OC1=CC=C(C(O)=C1)C1=C(O)C(=O)C2=C(O1)C=C(O)C=C2O | Flavonoid | 28% at 200 uM | NA | NA | >200 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000410 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Hieracin | 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one | OC1=CC2=C(C(O)=C1)C(=O)C=C(O2)C1=CC(O)=C(O)C(O)=C1 | Flavonoid | 48% at 200 uM | NA | NA | 28.2 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000411 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Luleolin | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one | OC1=CC2=C(C(O)=C1)C(=O)C=C(O2)C1=CC=C(O)C(O)=C1 | Flavonoid | 54% at 200 uM | NA | NA | 9.4 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000412 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | Taxifolin | 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-1-benzopyran-4-one | OC1C(OC2=C(C(O)=CC(O)=C2)C1=O)C1=CC(O)=C(O)C=C1 | Flavonoid | 12% at 200 uM | NA | NA | >200 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000413 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | (+) Cafechin | 2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol | OC1CC2=C(OC1C1=CC(O)=C(O)C=C1)C=C(O)C=C2O | Flavonoid | NA | NA | NA | >200 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000414 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | (-)-Epigallocatechin | 2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol | OC1CC2=C(OC1C1=CC(O)=C(O)C(O)=C1)C=C(O)C=C2O | Flavonoid | 0 at 200 uM | NA | NA | >200 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000415 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | ECG | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate | OC1=CC2=C(CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)C(O2)C2=CC=C(O)C(O)=C2)C(O)=C1 | Flavonoid | 70 at 200 uM | NA | NA | 6 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000416 | 21338918 | Hsp70 | DnaK/ DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | EGCG | 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate | OC1=CC2=C(CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)C(O2)C2=CC(O)=C(O)C(O)=C2)C(O)=C1 | Flavonoid | 62 at 200 uM | NA | NA | 12 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000417 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | Apoptozole (Az) | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC | Imidazole | 32% at 100 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000418 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | Apoptozole (Az) | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC | Imidazole | 65% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000419 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 1 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[2,4-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=C(C=C(C=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Imidazole library | 17.5% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000420 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 2 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-methoxyphenyl)-2-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC=CC(=C1)C(F)(F)F)C1=CC=C(OC)C=C1 | Imidazole library | 12.5% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000421 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 3 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-methoxyphenyl)-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=C(OC)C=C1 | Imidazole library | 15% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000422 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 4 | 1,3-dimethyl 5-(1-{[4-({2-[2-(2-aminoethoxy)ethoxy]ethyl}carbamoyl)phenyl]methyl}-4,5-bis(4-methoxyphenyl)-1H-imidazol-2-yl)benzene-1,3-dicarboxylate | COC(=O)C1=CC(=CC(=C1)C(=O)OC)C1=NC(=C(N1CC1=CC=C(C=C1)C(=O)NCCOCCOCCN)C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1 | Imidazole library | 17.5% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000423 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 5 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[2-(3,5-dimethylphenyl)-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl]methyl}benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(C)=CC(C)=C1)C1=CC=C(OC)C=C1 | Imidazole library | 12.5% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000424 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 6 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[2-(3,5-dimethoxyphenyl)-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl]methyl}benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(OC)=CC(OC)=C1)C1=CC=C(OC)C=C1 | Imidazole library | 10% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000425 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 7 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-1H-imidazol-1-yl]methyl}benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(OC)=C(OC)C(OC)=C1)C1=CC=C(OC)C=C1 | Imidazole library | 5% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000426 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 8 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-chlorophenyl)-2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide | NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 | Imidazole library | 7.5% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000427 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 9 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(4-bromophenyl)-2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide | NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC=C(Br)C=C2)C2=CC=C(Br)C=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 | Imidazole library | 10% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000428 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 10 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(4-methylphenyl)-1H-imidazol-1-yl}methyl)benzamide | CC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)F)C1=CC=C(C)C=C1 | Imidazole library | 12.5% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000429 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 11 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-1-yl}methyl)benzamide | CN(C)C1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCCOCCN)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)F)C1=CC=C(C=C1)N(C)C | Imidazole library | 12.5% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000430 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 12 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(quinolin-6-yl)-1H-imidazol-1-yl}methyl)benzamide | NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC3=C(C=C2)N=CC=C3)C2=CC=C3N=CC=CC3=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 | Imidazole library | 7.5% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000431 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 13 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(naphthalen-2-yl)-1H-imidazol-1-yl}methyl)benzamide | NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC3=C(C=CC=C3)C=C2)C2=CC=C3C=CC=CC3=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 | Imidazole library | 10% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000432 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 14 | N-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-4-{[4,5-bis(2H-1,3-benzodioxol-5-yl)-2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]methyl}benzamide | NCCOCCOCCNC(=O)C1=CC=C(CN2C(=NC(=C2C2=CC3=C(OCO3)C=C2)C2=CC=C3OCOC3=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)F)C=C1 | Imidazole library | 10% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000433 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATPase activity | NA | 15 | 4-({2-[3-(difluoromethyl)-5-(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(N)=O)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)F)C1=CC=C(OC)C=C1 | Imidazole library | 15% at 100 uM | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000434 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | NA | Antiproliferative activity | Apoptozole (Az) | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC | Imidazole | NA | NA | NA | 7 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000435 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | NA | Antiproliferative activity | Apoptozole (Az) | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC | Imidazole | NA | NA | NA | 6 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000436 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | NA | Antiproliferative activity | Apoptozole (Az) | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC | Imidazole | NA | NA | NA | 6 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000437 | 25772468 | Hsp70 | Hsp70 | Human | Cytosol | NA | Antiproliferative activity | Apoptozole (Az) | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC | Imidazole | NA | NA | NA | 5 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000438 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 1 | [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate | C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O | Adenosine derivative | NA | NA | NA | 0.5 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000439 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 2 | [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate | C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O | Adenosine derivative | NA | NA | NA | 0.5 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000440 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 3 | (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol | NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1 | Adenosine derivative | NA | NA | NA | 560 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000441 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 4 | (2R,3R,4S,5R)-2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol | NC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O | Adenosine derivative | NA | NA | NA | 9.4 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000442 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 5 | (2R,3R,4S,5R)-2-[6-amino-8-(methylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol | CNC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O | Adenosine derivative | NA | NA | NA | 17 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000443 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 6 | (2R,3R,4S,5R)-2-[6-amino-8-(benzylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol | NC1=C2N=C(NCC3=CC=CC=C3)N([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1 | Adenosine derivative | NA | NA | NA | 10 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000444 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 7 | (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-5-hydroxymethyltetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)c(Cl)c4)nc12 | Adenosine derivative | NA | NA | NA | 9.1 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000445 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 8 | (2R,3R,4S,5R)-2-{6-Amino-8-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-purin-9-yl}-5- hydroxymethyltetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5OCOc5c4)nc12 | Adenosine derivative | NA | NA | NA | 4.9 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000446 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 9 | (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)amino]purin-9-yl}-5-hydroxymethyltetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5ncccc5c4)nc12 | Adenosine derivative | NA | NA | NA | 2.9 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000447 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 10 | (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-methoxymethyltetrahydrofuran-3,4-diol | COC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2c(NCc3ccc(Cl)c(Cl)c3)nc4c(N)ncnc24 | Adenosine derivative | NA | NA | NA | 3.2 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000448 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 11 | (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-benzyloxymethyltetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccccc4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 | Adenosine derivative | NA | NA | NA | 2.4 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000449 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 12 | 4-{(2R,3S,4R,5R)-5-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-3,4- dihydroxytetrahydrofuran-2-ylmethoxymethyl}benzonitrile | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 | Adenosine derivative | NA | NA | NA | 0.5 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000450 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 13 | 4-[(2R,3S,4R,5R)-5-(6-Amino-8-benzylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2- ylmethoxymethyl]-benzonitrile | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccccc5)nc12 | Adenosine derivative | NA | NA | NA | 1.3 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000451 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 14 | (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-(3,4,5-trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 | Adenosine derivative | NA | NA | NA | 1.7 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000452 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 15 | 4-((2R,3S,4R,5R)-5-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-3,4-dihydroxytetrahydrofuran-2-ylmethoxymethyl)-benzonitrile | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 | Adenosine derivative | NA | NA | NA | 0.9 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000453 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 16 | (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(4-trifluoromethylbenzyloxymethyl)-tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C(F)(F)F)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 | Adenosine derivative | NA | NA | NA | 0.6 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000454 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | 17 | (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(3,4,5- trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 | Adenosine derivative | NA | NA | NA | <0.4 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000455 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Binding affinity | NA | 2 | [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate | C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O | Adenosine derivative | NA | 0.5 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | HSP70 Biacore Direct Binding Assay | NA | NA |
| HSPMDB000456 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Binding affinity | NA | 4 | (2R,3R,4S,5R)-2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol | NC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O | Adenosine derivative | NA | 11 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | HSP70 Biacore Direct Binding Assay | NA | NA |
| HSPMDB000457 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Binding affinity | NA | 12 | 4-{(2R,3S,4R,5R)-5-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-3,4- dihydroxytetrahydrofuran-2-ylmethoxymethyl}benzonitrile | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 | Adenosine derivative | NA | 0.3 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | HSP70 Biacore Direct Binding Assay | NA | NA |
| HSPMDB000458 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Binding affinity | NA | 13 | 4-[(2R,3S,4R,5R)-5-(6-Amino-8-benzylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2- ylmethoxymethyl]-benzonitrile | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccccc5)nc12 | Adenosine derivative | NA | 0.2 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | HSP70 Biacore Direct Binding Assay | NA | NA |
| HSPMDB000459 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Binding affinity | NA | 14 | (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-(3,4,5-trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 | Adenosine derivative | NA | 4.2 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | HSP70 Biacore Direct Binding Assay | NA | NA |
| HSPMDB000460 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Binding affinity | NA | 15 | 4-((2R,3S,4R,5R)-5-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-3,4-dihydroxytetrahydrofuran-2-ylmethoxymethyl)-benzonitrile | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 | Adenosine derivative | NA | 0.05 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | HSP70 Biacore Direct Binding Assay | NA | NA |
| HSPMDB000461 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Binding affinity | NA | 16 | (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(4-trifluoromethylbenzyloxymethyl)-tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C(F)(F)F)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 | Adenosine derivative | NA | 0.06 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | HSP70 Biacore Direct Binding Assay | NA | NA |
| HSPMDB000462 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | Binding affinity | NA | 17 | (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(3,4,5- trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 | Adenosine derivative | NA | 0.12 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | HSP70 Biacore Direct Binding Assay | NA | NA |
| HSPMDB000463 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 4 | (2R,3R,4S,5R)-2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol | NC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | 0.05 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000464 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 5 | (2R,3R,4S,5R)-2-[6-amino-8-(methylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol | CNC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | 13 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000465 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 6 | (2R,3R,4S,5R)-2-[6-amino-8-(benzylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol | NC1=C2N=C(NCC3=CC=CC=C3)N([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | >80 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000466 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 7 | (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-5-hydroxymethyltetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)c(Cl)c4)nc12 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | 26 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000467 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 8 | (2R,3R,4S,5R)-2-{6-Amino-8-[(benzo[1,3]dioxol-5-ylmethyl)-amino]-purin-9-yl}-5- hydroxymethyltetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5OCOc5c4)nc12 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | >80 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000468 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 9 | (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)amino]purin-9-yl}-5-hydroxymethyltetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5ncccc5c4)nc12 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | >80 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000469 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 10 | (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-methoxymethyltetrahydrofuran-3,4-diol | COC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2c(NCc3ccc(Cl)c(Cl)c3)nc4c(N)ncnc24 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | >80 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000470 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 11 | (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-benzyloxymethyltetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccccc4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | >80 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000471 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 12 | 4-{(2R,3S,4R,5R)-5-[6-Amino-8-(3,4-dichlorobenzylamino)purin-9-yl]-3,4- dihydroxytetrahydrofuran-2-ylmethoxymethyl}benzonitrile | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | 5 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000472 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 13 | 4-[(2R,3S,4R,5R)-5-(6-Amino-8-benzylamino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2- ylmethoxymethyl]-benzonitrile | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccccc5)nc12 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | > 80 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000473 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 14 | (2R,3R,4S,5R)-2-[6-Amino-8-(3,4-dichlorobenzylamino)-purin-9-yl]-5-(3,4,5-trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | 13 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000474 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 15 | 4-((2R,3S,4R,5R)-5-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-3,4-dihydroxytetrahydrofuran-2-ylmethoxymethyl)-benzonitrile | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | >80 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000475 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 16 | (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(4-trifluoromethylbenzyloxymethyl)-tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C(F)(F)F)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | 27 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000476 | 19256508 | Hsp70 | Hsc70 | Human | Cytosol | NA | Antiproliferative activity | 17 | (2R,3R,4S,5R)-2-{6-Amino-8-[(quinolin-6-ylmethyl)-amino]-purin-9-yl}-5-(3,4,5- trifluorobenzyloxymethyl)-tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](COCc4cc(F)c(F)c(F)c4)[C@@H](O)[C@H]3O)c(NCc5ccc6ncccc6c5)nc12 | Adenosine derivative | NA | NA | NA | NA | NA | NA | NA | 18 | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB000477 | 20012863 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of ATP binding | NA | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | NA | NA | NA | 0.5 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000478 | 20012863 | Hsp70 | Hsc70 | Human | Cytosol | Inhibition of ATP binding | NA | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | NA | NA | NA | 2.6 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000479 | 20012863 | Hsp70 | Hsp70 | Human | Cytosol | Binding affinity | NA | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | NA | 0.3 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000480 | 20012863 | Hsp70 | GRP78 | Human | Endoplasmic reticulum | Inhibition of ATP binding | NA | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | NA | NA | NA | 2.6 | NA | NA | NA | NA | Nucleotide binding domain | Fluorescence polarization (FP) assay | NA | NA |
| HSPMDB000481 | 20012863 | Hsp70 | Hsp70 | Human | Cytosol | NA | Antiproliferative activity | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | NA | NA | NA | NA | NA | NA | NA | 10.4 | Nucleotide binding domain | NA | NA | Cell cycle analysis |
| HSPMDB000482 | 20012863 | Hsp70 | Hsp70 | Human | Cytosol | NA | Antiproliferative activity | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | NA | NA | NA | NA | NA | NA | NA | 14.4 | Nucleotide binding domain | NA | NA | Cell cycle analysis |
| HSPMDB000483 | 20012863 | Hsp70 | Hsp70 | Human | Cytosol | NA | Antiproliferative activity | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | NA | NA | NA | NA | NA | NA | NA | 5.3 | Nucleotide binding domain | NA | NA | Cell cycle analysis |
| HSPMDB000484 | 20012863 | Hsp70 | Hsp70 | Human | Cytosol | NA | Antiproliferative activity | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | NA | NA | NA | NA | NA | NA | NA | 12.8 | Nucleotide binding domain | NA | NA | Cell cycle analysis |
| HSPMDB000485 | 20012863 | Hsp70 | Hsc70 (HSPA8) and Hsp70 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | VER-82160 | 2-amino-4-{2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl}-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide | CCNC(=O)C1=CC2=C(S1)N=C(N)N=C2C1=C(Cl)C=C(Cl)C(OCCN(CC)CC)=C1 | Dibenzyl-8-amino adenosine analogue | NA | NA | NA | NA | NA | NA | NA | 0.073 | NA | NA | NA | Cell cycle analysis |
| HSPMDB000486 | 20012863 | Hsp70 | Hsc70 (HSPA8) and Hsp70 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | VER-82160 | 2-amino-4-{2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl}-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide | CCNC(=O)C1=CC2=C(S1)N=C(N)N=C2C1=C(Cl)C=C(Cl)C(OCCN(CC)CC)=C1 | Dibenzyl-8-amino adenosine analogue | NA | NA | NA | NA | NA | NA | NA | 0.123 | NA | NA | NA | Cell cycle analysis |
| HSPMDB000487 | 20012863 | Hsp70 | Hsc70 (HSPA8) and Hsp70 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | VER-82160 | 2-amino-4-{2,4-dichloro-5-[2-(diethylamino)ethoxy]phenyl}-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide | CCNC(=O)C1=CC2=C(S1)N=C(N)N=C2C1=C(Cl)C=C(Cl)C(OCCN(CC)CC)=C1 | Dibenzyl-8-amino adenosine analogue | NA | NA | NA | NA | NA | NA | NA | 0.154 | NA | NA | NA | Cell cycle analysis |
| HSPMDB000488 | 20026329 | Hsp70 | Hsp70-Hsp40 | Porcine | Cytosol | Inhibition of chaperone activity | NA | Gentamycin | 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol | CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC | Aminoglycoside antibiotic | 25.8% at 5 mM | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | Refolding assay (luciferase) | NA | NA |
| HSPMDB000489 | 20026329 | Hsp70 | Hsp70-Hsp40 | Porcine | Cytosol | Inhibition of chaperone activity | NA | Gentamycin | 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol | CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC | Aminoglycoside antibiotic | 10.5% at 10 mM | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | Refolding assay (luciferase) | NA | NA |
| HSPMDB000490 | 14966137 | Hsp70 | Hsp73 | Porcine | Cytosol | Inhibition of chaperone activity | NA | Gentamycin | 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol | CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC | Aminoglycoside antibiotic | 100% at 500 uM | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | Substrate aggregation suppression assay | NA | NA |
| HSPMDB000491 | 29042222 | Hsp70 | Hsp70-Dnak | Human and Mtb | Cytosol | Inhibition of ATP binding | NA | Rickenyl A | 4',5,6-trimethoxy-4-(4-methoxyphenyl)-[1,1'-biphenyl]-2,3-diol | COC1=CC=C(C=C1)C1=C(O)C(O)=C(C(OC)=C1OC)C1=CC=C(OC)C=C1 | NA | NA | NA | NA | NA | 49 | NA | NA | NA | Nucleotide binding domain | Microarray based ATP binding test | NA | NA |
| HSPMDB000492 | 29953808 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of HSP 70 BAG interaction | NA | JG-194 | 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | 0.46 | NA | NA | NA | NA | NA | Allosteric site | Hsp70-BAG interaction assay | NA | NA |
| HSPMDB000493 | 29953808 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of HSP 70 BAG interaction | NA | JG-231 | 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | 0.11 | NA | NA | NA | NA | NA | Allosteric site | Hsp70-BAG interaction assay | NA | NA |
| HSPMDB000494 | 29953808 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of HSP 70 BAG interaction | NA | JG-294 | 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | 0.35 | NA | NA | NA | NA | NA | Allosteric site | Hsp70-BAG interaction assay | NA | NA |
| HSPMDB000495 | 29953808 | Hsp70 | Hsp70 | Human | Cytosol | Inhibition of HSP 70 BAG interaction | NA | JG-345 | 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | 1.11 | NA | NA | NA | NA | NA | Allosteric site | Hsp70-BAG interaction assay | NA | NA |
| HSPMDB000496 | 28455613 | Hsp70 | PfHsp70-1 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | Polymixin B | N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide | CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(Cc2ccccc2)NC(=O)C(CCN)NC1=O)C(C)O | Lipopeptide anrtibiotic | 100% at 25 uM | 0.38 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000497 | 28455613 | Hsp70 | PfHsp70-z | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | Polymixin B | N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide | CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(Cc2ccccc2)NC(=O)C(CCN)NC1=O)C(C)O | Lipopeptide anrtibiotic | 100% at 25 uM | 0.94 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000498 | 25500222 | Hsp70 | Hsp70i | Human | Cell surface | Inhibition of ATP binding | Inhibition of tumor growth | HS-72 | ((S)-N-(1-propyl-1Hbenzo[d]imidazol-2-yl)-1-(pyrazin-2-yl)piperidine-3-carboxamide) | CCCn1c(NC(=O)[C@H]2CCCN(C2)c3cnccn3)nc4ccccc14 | Purine analogue | NA | NA | NA | NA | NA | NA | NA | NA | Allosteric site | Fluorescence linked enzyme chemoproteomic strategy (FLECS) | NA | NA |
| HSPMDB000499 | 26839186 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | 9-aminoacridizinium derivative 1 | 9-amino acridizinium tetrafluoroborate | NA | 9-aminoacridizinium derivative | NA | NA | NA | 45 | NA | NA | NA | NA | Nucleotide binding domain | Refolding assay (luciferase) | NA | NA |
| HSPMDB000500 | 26839186 | Hsp70 | Hsc70 | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | 9-aminoacridizinium derivative 1 | 9-amino acridizinium tetrafluoroborate | NA | 9-aminoacridizinium derivative | NA | NA | NA | 363 | NA | NA | NA | NA | Nucleotide binding domain | Refolding assay (luciferase) | NA | NA |
| HSPMDB000501 | 26839186 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | alkylamino-substituted acridizinium derivative 2 | 9-(pyrrolidin-1-yl)-5??-pyrido[1,2-b]isoquinolin-5-ylium bromide | [Br-].C1CCN(C1)C1=CC2=CC3=CC=CC=[N+]3C=C2C=C1 | 9-aminoacridizinium derivative | NA | NA | NA | 127 | NA | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000502 | 26839186 | Hsp70 | Hsc70 | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | alkylamino-substituted acridizinium derivative 2 | 9-(pyrrolidin-1-yl)-5??-pyrido[1,2-b]isoquinolin-5-ylium bromide | [Br-].C1CCN(C1)C1=CC2=CC3=CC=CC=[N+]3C=C2C=C1 | 9-aminoacridizinium derivative | NA | NA | NA | 34 | NA | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000503 | 26839186 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | sulfanyl-substituted derivative 3 | 9-(methylsulfanyl)acridizinium tetrafluoroborate | NA | 9-aminoacridizinium derivative | NA | NA | NA | 1052 | NA | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000504 | 26839186 | Hsp70 | Hsc70 | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | sulfanyl-substituted derivative 3 | 9-(methylsulfanyl)acridizinium tetrafluoroborate | NA | 9-aminoacridizinium derivative | NA | NA | NA | 931 | NA | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000505 | 10086320 | Hsp70 | Hsc70 | Bovine | Cytosol and nucleus | Activation of ATPase activity | NA | 15-deoxyspergualin (DSG) | N-[(1S)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide | C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O | Natural product | 22% increase | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | ATPase assay | NA | NA |
| HSPMDB000506 | 10086320 | Hsp70 | Ssa1p | Yeast | Cytosol | Activation of ATPase activity | NA | 15-deoxyspergualin (DSG) | N-[(1S)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide | C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O | Natural product | 42% increase | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | ATPase assay | NA | NA |
| HSPMDB000507 | 18729127 | Hsp70 | Hsc70 | Human | Cytosol and nucleus | Binding affinity | NA | Apoptozole (Az) | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC | Imidazole | NA | 0.21 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000508 | 18729127 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | Binding affinity | NA | Apoptozole (Az) | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COC1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)CC4=CC=C(C=C4)C(=O)N)C5=CC=C(C=C5)OC | Imidazole | NA | 0.14 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000509 | 23177194 | Hsp70 | Hsp72 (HSPA1A) | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | Methylene Blue | [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride | CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] | Dihydropyrimidine derivative | 37.50% | NA | NA | NA | NA | NA | NA | NA | Irreversibly inhibits by oxidizing Cys306 | ATPase assay | NA | NA |
| HSPMDB000510 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | MKT-077 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine | NA | NA | NA | 6.4 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Enzyme-linked immunosorbent assay (ELISA) | NA | NA |
| HSPMDB000511 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | YM-01 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | 3.2 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Enzyme-linked immunosorbent assay (ELISA) | NA | NA |
| HSPMDB000512 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | YM-08 | (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one | CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 | Rhodacyanine derivative | NA | NA | NA | 0.61 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Enzyme-linked immunosorbent assay (ELISA) | NA | NA |
| HSPMDB000513 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | YM-02 | 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one | CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C | Rhodacyanine derivative | NA | NA | NA | >50 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Enzyme-linked immunosorbent assay (ELISA) | NA | NA |
| HSPMDB000514 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | YM-03 | 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium | CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C | Rhodacyanine derivative | NA | NA | NA | >50 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Enzyme-linked immunosorbent assay (ELISA) | NA | NA |
| HSPMDB000515 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | YM-04 | 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide | [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | 15 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Enzyme-linked immunosorbent assay (ELISA) | NA | NA |
| HSPMDB000516 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | YM-07 | (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one | CCN1C(=O)CS\C1=C/C1=NC=CC=C1 | Rhodacyanine derivative | NA | NA | NA | 5.8 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Enzyme-linked immunosorbent assay (ELISA) | NA | NA |
| HSPMDB000517 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | MKT-077 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine | NA | NA | NA | NA | 2.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000518 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-01 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 5.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000519 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-08 | (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one | CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 10.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000520 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-02 | 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one | CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C | Rhodacyanine derivative | NA | NA | NA | NA | 5.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000521 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-03 | 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium | CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000522 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-04 | 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide | [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000523 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-07 | (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one | CCN1C(=O)CS\C1=C/C1=NC=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 6.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000524 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | MKT-077 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine | NA | NA | NA | NA | 3 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000525 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-01 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 3.3 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000526 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-08 | (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one | CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 7.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000527 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-02 | 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one | CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C | Rhodacyanine derivative | NA | NA | NA | NA | 13.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000528 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-03 | 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium | CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000529 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-04 | 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide | [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000530 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-07 | (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one | CCN1C(=O)CS\C1=C/C1=NC=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000531 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | MKT-077 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine | NA | NA | NA | NA | 1.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000532 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-01 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000533 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-08 | (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one | CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 8.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000534 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-02 | 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one | CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000535 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-03 | 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium | CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000536 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-04 | 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide | [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000537 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-07 | (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one | CCN1C(=O)CS\C1=C/C1=NC=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000538 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | MKT-077 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine | NA | NA | NA | NA | 8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000539 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-01 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 3.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000540 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-08 | (2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one | CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=NC=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 15 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000541 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-02 | 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-sulfanylidene-1,3-thiazolidin-4-one | CCN1C(=S)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000542 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-03 | 3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-2-(methylsulfanyl)-4-oxo-4,5-dihydro-1,3-thiazol-3-ium | CC[N+]1=C(SC)S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C | Rhodacyanine derivative | NA | NA | NA | NA | 22 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000543 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-04 | 2-{[(2Z)-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium iodide | [I-].CCN1C(=O)CS\C1=C/C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000544 | 23472668 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-07 | (2Z)-3-ethyl-2-[(pyridin-2-yl)methylidene]-1,3-thiazolidin-4-one | CCN1C(=O)CS\C1=C/C1=NC=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000545 | 23607970 | Hsp70 | Ssa1-Hlj1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | MKT-077 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine | 10-15% | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000546 | 23607970 | Hsp70 | Ssa1-Hlj1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | YM-01 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(C=CC=C2)N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | 10-15% | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB000547 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | DMT3024 | benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 | Pyrimidinone amide | 0.73 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000548 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | DMT2264 | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Pyrimidinone amide | 0.74 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000549 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL2-29 | 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid | CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O | Pyrimidinone amide | 1.01 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000550 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL2-39 | benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Pyrimidinone amide | 0.92 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000551 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL2-61 | ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O | Pyrimidinone amide | 0.99 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000552 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL2-213 | ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O | Pyrimidinone amide | 1.02 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000553 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL2-215 | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 | Pyrimidinone amide | 1.01 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000554 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL3-39 | benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 | Pyrimidinone amide | 0.72 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000555 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | Inhibition of ATPase activity | NA | JAB75 | methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 | Pyrimidinone amide | 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000556 | 19195901 | Hsp70 | Ssa1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | DMT3024 | benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 | Pyrimidinone amide | 1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000557 | 19195901 | Hsp70 | Ssa1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | DMT2264 | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Pyrimidinone amide | 0.97 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000558 | 19195901 | Hsp70 | Ssa1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | MAL2-29 | 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid | CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O | Pyrimidinone amide | 0.93 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000559 | 19195901 | Hsp70 | Ssa1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | MAL2-39 | benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Pyrimidinone amide | 0.95 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000560 | 19195901 | Hsp70 | Ssa1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | MAL2-61 | ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O | Pyrimidinone amide | 1.1 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000561 | 19195901 | Hsp70 | Ssa1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | MAL2-213 | ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O | Pyrimidinone amide | 0.89 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000562 | 19195901 | Hsp70 | Ssa1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | MAL2-215 | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 | Pyrimidinone amide | 1.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000563 | 19195901 | Hsp70 | Ssa1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | MAL3-39 | benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 | Pyrimidinone amide | 0.75 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000564 | 19195901 | Hsp70 | Ssa1 | Yeast | Cytosol | Inhibition of ATPase activity | NA | JAB75 | methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 | Pyrimidinone amide | 1.2 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000565 | 19195901 | Hsp70 | Hsp70 (HSPA1A) | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | DMT3024 | benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 | Pyrimidinone amide | 0.74 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000566 | 19195901 | Hsp70 | Hsp70 (HSPA1A) | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | DMT2264 | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Pyrimidinone amide | 0.95 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000567 | 19195901 | Hsp70 | Hsp70 (HSPA1A) | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL2-29 | 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid | CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O | Pyrimidinone amide | 0.85 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000568 | 19195901 | Hsp70 | Hsp70 (HSPA1A) | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL2-39 | benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Pyrimidinone amide | 0.8 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000569 | 19195901 | Hsp70 | Hsp70 (HSPA1A) | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL2-61 | ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O | Pyrimidinone amide | 0.74 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000570 | 19195901 | Hsp70 | Hsp70 (HSPA1A) | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL2-213 | ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O | Pyrimidinone amide | 0.8 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000571 | 19195901 | Hsp70 | Hsp70 (HSPA1A) | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL2-215 | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 | Pyrimidinone amide | 0.72 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000572 | 19195901 | Hsp70 | Hsp70 (HSPA1A) | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL3-39 | benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 | Pyrimidinone amide | 0.82 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000573 | 19195901 | Hsp70 | Hsp70 (HSPA1A) | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | JAB75 | methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 | Pyrimidinone amide | 0.7 | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000574 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | NA | Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) | DMT3024 | benzyl 1-{5-[({[1,1'-biphenyl]-4-yl}(butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]pentyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCNC(=O)C(N(CCN1CCOCC1)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)[N+]([O-])=O)C(C(=O)OCC2=CC=CC=C2)=C1C)C1=CC=C(C=C1)C1=CC=CC=C1 | Pyrimidinone amide | NA | NA | NA | 0.2 | NA | NA | NA | NA | NA | NA | NA | [3H]hypoxanthine uptake assay |
| HSPMDB000575 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | NA | Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) | DMT2264 | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-(5-{[(butylcarbamoyl)(cyclohexyl)methyl](hexyl)carbamoyl}pentyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCCCN(C(C1CCCCC1)C(=O)NCCCC)C(=O)CCCCCN1C(=O)NC(C2=CC=C(C=C2)C2=CC=CC=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Pyrimidinone amide | NA | NA | NA | 1.1 | NA | NA | NA | NA | NA | NA | NA | [3H]hypoxanthine uptake assay |
| HSPMDB000576 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | NA | Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) | MAL2-29 | 6-[5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]hexanoic acid | CCOC(=O)C1=C(C)N(CCCCCC(O)=O)C(=O)NC1C1=CC=CC(=C1)[N+]([O-])=O | Pyrimidinone amide | NA | NA | NA | 1.6 | NA | NA | NA | NA | NA | NA | NA | [3H]hypoxanthine uptake assay |
| HSPMDB000577 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | NA | Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) | MAL2-39 | benzyl 1-butyl-4-(4-methoxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCCCN1C(=O)NC(C2=CC=C(OC)C=C2)C(C(=O)OCC2=CC=CC=C2)=C1C | Pyrimidinone amide | NA | NA | NA | 0.2 | NA | NA | NA | NA | NA | NA | NA | [3H]hypoxanthine uptake assay |
| HSPMDB000578 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | NA | Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) | MAL2-61 | ethyl 1-benzyl-6-methyl-4-{2-[(2-nitrobenzenesulfonyl)oxy]phenyl}-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCOC(=O)C1=C(C)N(CC2=CC=CC=C2)C(=O)NC1C1=CC=CC=C1OS(=O)(=O)C1=C(C=CC=C1)[N+]([O-])=O | Pyrimidinone amide | NA | NA | NA | 0.1 | NA | NA | NA | NA | NA | NA | NA | [3H]hypoxanthine uptake assay |
| HSPMDB000579 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | NA | Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) | MAL2-213 | ethyl 1-[3-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)propyl]-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CCOC(=O)C1=C(C)N(CCCC(=O)NCCN2C(C)=C(C=C2C2=CC=CC=C2)C(=O)OC)C(=O)NC1C1=CC=C(C=C1)[N+]([O-])=O | Pyrimidinone amide | NA | NA | NA | 0.03 | NA | NA | NA | NA | NA | NA | NA | [3H]hypoxanthine uptake assay |
| HSPMDB000580 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | NA | Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) | MAL2-215 | benzyl 4-{[1,1'-biphenyl]-4-yl}-1-[5-({2-[3-(methoxycarbonyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl]ethyl}carbamoyl)pentyl]-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | COC(=O)C1=C(C)N(CCNC(=O)CCCCCN2C(=O)NC(C3=CC=C(C=C3)C3=CC=CC=C3)C(C(=O)OCC3=CC=CC=C3)=C2C)C(=C1)C1=CC=CC=C1 | Pyrimidinone amide | NA | NA | NA | 0.05 | NA | NA | NA | NA | NA | NA | NA | [3H]hypoxanthine uptake assay |
| HSPMDB000581 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | NA | Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) | MAL3-39 | benzyl 1-{3-[({[1,1'-biphenyl]-4-yl}(tert-butylcarbamoyl)methyl)[2-(morpholin-4-yl)ethyl]carbamoyl]propyl}-6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | CC1=C(C(NC(=O)N1CCCC(=O)N(CCN1CCOCC1)C(C(=O)NC(C)(C)C)C1=CC=C(C=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 | Pyrimidinone amide | NA | NA | NA | 0.8 | NA | NA | NA | NA | NA | NA | NA | [3H]hypoxanthine uptake assay |
| HSPMDB000582 | 19195901 | Hsp70 | PfHsp70 | Plasmodium falciparum | Cytosol and nucleus | NA | Antiparasitic activity (inhibition of [3H]hypoxanthine uptake) | JAB75 | methyl 6-benzyl-4-(naphthalen-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | COC(=O)C1=C(CC2=CC=CC=C2)NC(=O)NC1C1=CC2=C(C=CC=C2)C=C1 | Pyrimidinone amide | NA | NA | NA | 0.3 | NA | NA | NA | NA | NA | NA | NA | [3H]hypoxanthine uptake assay |
| HSPMDB000583 | 24265689 | Hsp70 | Hsp70(1-382) | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | Significant Inhibition at 20 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Refolding assay (luciferase) | NA | NA |
| HSPMDB000584 | 24265689 | Hsp70 | Hsc70 | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | Significant Inhibition at 20 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Refolding assay (luciferase) | NA | NA |
| HSPMDB000585 | 24265689 | Hsp70 | Hsp70(1-382) | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | PES | 2-phenylethynesulfonamide | C1=CC=C(C=C1)C#CS(=O)(=O)N | NA | Significant Inhibition at 160 uM | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | Refolding assay (luciferase) | NA | NA |
| HSPMDB000586 | 24265689 | Hsp70 | Hsc70 | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | PES | 2-phenylethynesulfonamide | C1=CC=C(C=C1)C#CS(=O)(=O)N | NA | Significant Inhibition at 160 uM | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | Refolding assay (luciferase) | NA | NA |
| HSPMDB000587 | 24265689 | Hsp70 | Hsp70 | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | NA | NA | 10 | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000588 | 24265689 | Hsp70 | Hsp70 and Hdj1 | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | C1=CC(=CC=C1COCC2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3NCC5=CC(=C(C=C5)Cl)Cl)O)O)C#N | Dibenzyl-8-amino adenosine analogue | NA | NA | 2.87 | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000589 | 18060774 | Hsp70 | Hsc70 | Bovine | Cytosol and nucleus | Activation of ATPase activity | NA | 2(SW02) | ethyl 6-(4-bromophenyl)-3-(4-methoxy-4-oxobutyl)-4-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate | CCOC(=O)C1=C(N(C(=O)NC1C2=CC=C(C=C2)Br)CCCC(=O)OC)C | Dihydropyrimidine | NA | NA | NA | NA | 213 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000590 | 18060774 | Hsp70 | Hsc70 | Bovine | Cytosol and nucleus | Inhibition of ATPase activity | NA | 6 | 3-[(3S)-3-[(3S)-7-amino-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}heptanamido]-5-phenylpentanamido]propanoic acid | CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCCCN)CC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 | Dihydropyrimidine | NA | NA | NA | NA | 105 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000591 | 18060774 | Hsp70 | Hsc70 | Bovine | Cytosol and nucleus | Inhibition of ATPase activity | NA | 7 | 3-[(3S)-7-amino-3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-phenylpentanamido]heptanamido]propanoic acid | CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)N[C@@H](CCCCN)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 | Dihydropyrimidine | NA | NA | NA | NA | 265 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000592 | 18060774 | Hsp70 | Hsc70 | Bovine | Cytosol and nucleus | Activation of ATPase activity | NA | 8 | 3-[(3R,4S)-3-[(3S)-6-amino-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}hexanamido]-4-methylhexanamido]propanoic acid | CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCCN)CC(=O)N[C@H](CC(=O)NCCC(O)=O)[C@@H](C)CC)C(=O)NC1C1=CC=C(Br)C=C1 | Dihydropyrimidine | NA | NA | NA | NA | 352 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000593 | 18060774 | Hsp70 | Hsc70 | Bovine | Cytosol and nucleus | Activation of ATPase activity | NA | 9 | 3-[(3S)-3-[(3R)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-4-methylpentanamido]-4-(naphthalen-1-yl)butanamido]propanoic acid | CCOC(=O)C1=C(C)N(CCCC(=O)N[C@H](CC(=O)N[C@H](CC(=O)NCCC(O)=O)CC2=C3C=CC=CC3=CC=C2)C(C)C)C(=O)NC1C1=CC=C(Br)C=C1 | Dihydropyrimidine | NA | NA | NA | NA | 255 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000594 | 18060774 | Hsp70 | Hsc70 | Bovine | Cytosol and nucleus | Activation of ATPase activity | NA | 14 | 3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-phenylpentanamido]propanoic acid | CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 | Dihydropyrimidine | NA | NA | NA | NA | 190 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000595 | 18060774 | Hsp70 | Hsc70 | Bovine | Cytosol and nucleus | Activation of ATPase activity | NA | 15 | 3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-4-(naphthalen-1-yl)butanamido]propanoic aci | CCOC(=O)C1=C(C)N(CCCC(=O)N[C@H](CC(=O)NCCC(O)=O)CC2=C3C=CC=CC3=CC=C2)C(=O)NC1C1=CC=C(Br)C=C1 | Dihydropyrimidine | NA | NA | NA | NA | 179 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000596 | 18060774 | Hsp70 | Hsc70 | Bovine | Cytosol and nucleus | Inhibition of ATPase activity | NA | MAL3-101 | Benzyl 4-([1,1?-biphenyl]-4-yl)-1-(6-((2-(butylamino)-1-(4-(2-methoxy-2-oxoethoxy)-3-(methoxycarbonyl)phenyl)-2-oxoethyl)(hexyl)amino)-6-oxohexyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate | O=C(C1=C(C)N(CCCCCC(N(C(C2=CC=C(OCC(OC)=O)C(C(OC)=O)=C2)C(NCCCC)=O)CCCCCC)=O)C(NC1C3=CC=C(C4=CC=CC=C4)C=C3)=O)OCC5=CC=CC=C5 | Dihydropyrimidine | NA | NA | NA | NA | 74 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000597 | 18060774 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 6 | 3-[(3S)-3-[(3S)-7-amino-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}heptanamido]-5-phenylpentanamido]propanoic acid | CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCCCN)CC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 | Dihydropyrimidine | NA | NA | NA | NA | 107 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000598 | 18060774 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 7 | 3-[(3S)-7-amino-3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-5-phenylpentanamido]heptanamido]propanoic acid | CCOC(=O)C1=C(C)N(CCCC(=O)N[C@@H](CCC2=CC=CC=C2)CC(=O)N[C@@H](CCCCN)CC(=O)NCCC(O)=O)C(=O)NC1C1=CC=C(Br)C=C1 | Dihydropyrimidine | NA | NA | NA | NA | 325 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000599 | 18060774 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Activation of ATPase activity | NA | 15 | 3-[(3S)-3-{4-[4-(4-bromophenyl)-5-(ethoxycarbonyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]butanamido}-4-(naphthalen-1-yl)butanamido]propanoic aci | CCOC(=O)C1=C(C)N(CCCC(=O)N[C@H](CC(=O)NCCC(O)=O)CC2=C3C=CC=CC3=CC=C2)C(=O)NC1C1=CC=C(Br)C=C1 | Dihydropyrimidine | NA | NA | NA | NA | 190 | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000600 | 22546203 | Hsp70 | Hsp70-DnaJ (RRL) | Rabbit | Cytosol and nucleus | Inhibition of chaperone activity | NA | 1 | pentyl 3a,8b-dihydroxy-2-methyl-4-methylidene-1H,3aH,4H,8bH-indeno[1,2-b]pyrrole-3-carboxylate | CCCCCOC(=O)C1=C(C)NC2(O)C3=C(C=CC=C3)C(=C)C12O | Phenoxy-N-arylacetamide | NA | NA | NA | 4.3 | NA | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000601 | 22546203 | Hsp70 | Hsp70-DnaJ (RRL) | Rabbit | Cytosol and nucleus | Inhibition of chaperone activity | NA | 2 | N-(4-chlorophenyl)-4-(thiophen-2-yl)-1,3-thiazol-2-amine | ClC1=CC=C(NC2=NC(=CS2)C2=CC=CS2)C=C1 | Phenoxy-N-arylacetamide | NA | NA | NA | 4 | NA | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000602 | 22546203 | Hsp70 | Hsp70-DnaJ (RRL) | Rabbit | Cytosol and nucleus | Inhibition of chaperone activity | NA | 3 | 7-(2-chlorophenyl)-4-(furan-2-yl)-8-oxa-5,6-diazatricyclo[7.4.0.0²,?]trideca-1(9),4,10,12-tetraene | ClC1=C(C=CC=C1)C1OC2=C(C=CC=C2)C2CC(=NN12)C1=CC=CO1 | Phenoxy-N-arylacetamide | NA | NA | NA | 8.8 | NA | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000603 | 22546203 | Hsp70 | Hsp70-DnaJ (RRL) | Rabbit | Cytosol and nucleus | Inhibition of chaperone activity | NA | 4 | N-(cyclohexa-1,5-dien-1-yl)-4-(thiophen-2-yl)-1,3-thiazol-2-amine | C1CC=C(NC2=NC(=CS2)C2=CC=CS2)C=C1 | Phenoxy-N-arylacetamide | NA | NA | NA | 1.1 | NA | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000604 | 22546203 | Hsp70 | Hsp70-DnaJ (RRL) | Rabbit | Cytosol and nucleus | Inhibition of chaperone activity | NA | 5 | ethyl 3-[2-(2-chlorophenoxy)acetamido]benzoate | CCOC(=O)C1=CC=CC(NC(=O)COC2=CC=CC=C2Cl)=C1 | Phenoxy-N-arylacetamide | NA | NA | NA | 0.81 | NA | NA | NA | NA | NA | Refolding assay (luciferase) | NA | NA |
| HSPMDB000605 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | B12 | N-[(2-fluorophenyl)methyl]thiophene-2-carboxamide | FC1=CC=CC=C1CNC(=O)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 64.1 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000606 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | F6 | N-[(3,4-dichlorophenyl)methyl]thiophene-2-carboxamide | ClC1=CC=C(CNC(=O)C2=CC=CS2)C=C1Cl | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 7.3 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000607 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | F8 | N-[(2-hydroxyphenyl)methyl]thiophene-2-carboxamide | OC1=CC=CC=C1CNC(=O)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 2.3 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000608 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | F10 | 2-[4-(thiophene-2-carbonyl)piperazin-1-yl]ethan-1-ol | OCCN1CCN(CC1)C(=O)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 16.7 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000609 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | B1 | N-[1-(4-fluorophenyl)propan-2-yl]thiophene-2-carboxamide | CC(CC1=CC=C(F)C=C1)NC(=O)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 13.7 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000610 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | B1 | N-[1-(4-fluorophenyl)propan-2-yl]thiophene-2-carboxamide | CC(CC1=CC=C(F)C=C1)NC(=O)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 28 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000611 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | D10 | N-[(1-benzothiophen-7-yl)methyl]thiophene-2-carboxamide | O=C(NCC1=CC=CC2=C1SC=C2)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 0.2 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000612 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | B3 | N-[(4-fluorophenyl)methyl]-5-methylfuran-2-carboxamide | CC1=CC=C(O1)C(=O)NCC1=CC=C(F)C=C1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 47.6 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000613 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | B4 | N-[(4-chlorophenyl)methyl]-5-methylfuran-2-carboxamide | CC1=CC=C(O1)C(=O)NCC1=CC=C(Cl)C=C1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 19.3 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000614 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | F7 | N-[(2,6-dichlorophenyl)methyl]thiophene-2-carboxamide | ClC1=CC=CC(Cl)=C1CNC(=O)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 1.5 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000615 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | F9 | N-[(3,5-dichlorophenyl)methyl]thiophene-2-carboxamide | ClC1=CC(CNC(=O)C2=CC=CS2)=CC(Cl)=C1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 2.8 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000616 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | D5 | N-[(naphthalen-1-yl)methyl]thiophene-2-carboxamide | O=C(NCC1=CC=CC2=C1C=CC=C2)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 1 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000617 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | D5 | N-[(naphthalen-1-yl)methyl]thiophene-2-carboxamide | O=C(NCC1=CC=CC2=C1C=CC=C2)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 1.7 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000618 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | D9 | N-(quinazolin-2-yl)thiophene-2-carboxamide | O=C(NC1=NC2=C(C=CC=C2)C=N1)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 1.5 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000619 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | C5 | N-[(2-bromophenyl)methyl]thiophene-2-carboxamide | BrC1=CC=CC=C1CNC(=O)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 14.3 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000620 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | C5 | N-[(2-bromophenyl)methyl]thiophene-2-carboxamide | BrC1=CC=CC=C1CNC(=O)C1=CC=CS1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 39.3 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000621 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | NA | Antibacterial activity | BI-88E3 | N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide | CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | NA | Bacterial growth inhibition assay (OD based) |
| HSPMDB000622 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | NA | Antibacterial activity | BI-88E3 | N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide | CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | NA | Bacterial growth inhibition assay (OD based) |
| HSPMDB000623 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | NA | Antibacterial activity | BI-88E3 | N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide | CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | NA | Bacterial growth inhibition assay (OD based) |
| HSPMDB000624 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | NA | Antibacterial activity | BI-88E3 | N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide | CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | NA | Bacterial growth inhibition assay (OD based) |
| HSPMDB000625 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | NA | Antibacterial activity | BI-88E3 | N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide | CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | NA | Bacterial growth inhibition assay (OD based) |
| HSPMDB000626 | 19694756 | Hsp70 | DnaK (SBD) | Bacteria | Cytosol and membrane | Binding affinity | NA | BI-88E3 | N-[(4-methylphenyl)methyl]-5-nitrofuran-2-carboxamide | CC1=CC=C(CNC(=O)C2=CC=C(O2)[N+]([O-])=O)C=C1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 25 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000627 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | NA | Antibacterial activity | BI-88D7 | N-(1H-indol-5-yl)thiophene-2-carboxamide | N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | NA | Bacterial growth inhibition assay (OD based) |
| HSPMDB000628 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | NA | Antibacterial activity | BI-88D7 | N-(1H-indol-5-yl)thiophene-2-carboxamide | N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | NA | Bacterial growth inhibition assay (OD based) |
| HSPMDB000629 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | NA | Antibacterial activity | BI-88D7 | N-(1H-indol-5-yl)thiophene-2-carboxamide | N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | NA | Bacterial growth inhibition assay (OD based) |
| HSPMDB000630 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | NA | Antibacterial activity | BI-88D7 | N-(1H-indol-5-yl)thiophene-2-carboxamide | N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | NA | Bacterial growth inhibition assay (OD based) |
| HSPMDB000631 | 19694756 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | NA | Antibacterial activity | BI-88D7 | N-(1H-indol-5-yl)thiophene-2-carboxamide | N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | NA | Bacterial growth inhibition assay (OD based) |
| HSPMDB000632 | 19694756 | Hsp70 | DnaK (SBD) | Bacteria | Cytosol and membrane | Binding affinity | NA | BI-88D7 | N-(1H-indol-5-yl)thiophene-2-carboxamide | N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 4.9 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000633 | 19694756 | Hsp70 | DnaK (FL) | Bacteria | Cytosol and membrane | Binding affinity | NA | BI-88D7 | N-(1H-indol-5-yl)thiophene-2-carboxamide | N1C=CC2=CC(=CC=C12)NC(=O)C=1SC=CC1 | Chem Bridge, MayBridge, Life Chemicals and MicroSource, Gaylordsville, CT, USA | NA | 12.7 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB000634 | 20926844 | Hsp70 | DnaK-DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 2a | ethyl 2-amino-1-phenyl-1H-pyrrolo[2,3-b]quinoxaline-3-carboxylate | CCOC(=O)c1c(N)n(c2ccccc2)c3nc4ccccc4nc13 | MS2000 (Spectrum) library | NA | NA | NA | >500 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000635 | 20926844 | Hsp70 | DnaK-DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 2b | ethyl 2-amino-1-hexyl-1H-pyrrolo[2,3-b]quinoxaline-3-carboxylate | CCCCCCn1c(N)c(C(=O)OCC)c2nc3ccccc3nc12 | MS2000 (Spectrum) library | NA | NA | NA | >500 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000636 | 20926844 | Hsp70 | DnaK-DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 3a | 6-methyl-2-((2-oxo-2-phenylethyl)thio)-4-(trifluoromethyl)nicotinonitrile | Cc1cc(c(C#N)c(SCC(=O)c2ccccc2)n1)C(F)(F)F | MS2000 (Spectrum) library | NA | NA | NA | >500 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000637 | 20926844 | Hsp70 | DnaK-DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 3b | ethyl 6-acetyl-2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate | CCOC(=O)c1c(N)sc2CN(CCc12)C(C)=O | MS2000 (Spectrum) library | NA | NA | NA | >500 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000638 | 20926844 | Hsp70 | DnaK-DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 3c | cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate | COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C | MS2000 (Spectrum) library | NA | NA | NA | 37 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000639 | 20926845 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | 3c | cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate | COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C | MS2000 (Spectrum) library | NA | 13 | NA | NA | NA | NA | NA | NA | NA | Intrisic Trp fluortescence | NA | NA |
| HSPMDB000640 | 20926844 | Hsp70 | Hsp72 | Human | Cytosol and nucleus | Inhibition of ATPase activity | NA | 3c | cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate | COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C | MS2000 (Spectrum) library | NA | NA | NA | 71 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000641 | 20926844 | Hsp70 | Hsc70 | Bovine | Cytosol and nucleus | Inhibition of ATPase activity | NA | 3c | cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl) carbamate | COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)N[S](=O)(=O)c5ccccc5C | MS2000 (Spectrum) library | NA | NA | NA | 106 | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB000642 | 21636681 | Hsp70 | Hsc70 (HSPA8) and Hsp70 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2-phenylethyenesulfonamide (PES) | 2-phenylethynesulfonamide | C1=CC=C(C=C1)C#CS(=O)(=O)N | NA | NA | NA | NA | NA | NA | NA | NA | 8 | C-terminal domain | NA | NA | MTT viability assay |
| HSPMDB000643 | 21636681 | Hsp70 | Hsc70 (HSPA8) and Hsp70 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2-phenylethyenesulfonamide (PES) | 2-phenylethynesulfonamide | C1=CC=C(C=C1)C#CS(=O)(=O)N | NA | NA | NA | NA | NA | NA | NA | NA | 11 | C-terminal domain | NA | NA | MTT viability assay |
| HSPMDB000644 | 21636681 | Hsp70 | Hsc70 (HSPA8) and Hsp70 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2-phenylethyenesulfonamide (PES) | 2-phenylethynesulfonamide | C1=CC=C(C=C1)C#CS(=O)(=O)N | NA | NA | NA | NA | NA | NA | NA | NA | 5 | C-terminal domain | NA | NA | MTT viability assay |
| HSPMDB000645 | 21636681 | Hsp70 | Hsc70 (HSPA8) and Hsp70 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2-phenylethyenesulfonamide (PES) | 2-phenylethynesulfonamide | C1=CC=C(C=C1)C#CS(=O)(=O)N | NA | NA | NA | NA | NA | NA | NA | NA | 5 | C-terminal domain | NA | NA | MTT viability assay |
| HSPMDB000646 | 23819499 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity (ADP-bound DnaK) | NA | Zafirlukast (Zaf) | cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate | CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC | Library assembled at the University of Michigan's Center for Chemical Genomics | NA | 52 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Intrisic Trp fluortescence | NA | NA |
| HSPMDB000647 | 23819499 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity (ATP-bound DnaK) | NA | Zafirlukast (Zaf) | cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate | CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC | Library assembled at the University of Michigan's Center for Chemical Genomics | NA | >100 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Intrisic Trp fluortescence | NA | NA |
| HSPMDB000648 | 23819499 | Hsp70 | DnaK-DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (DnaJ stimulated) | NA | Zafirlukast (Zaf) | cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate | CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC | Library assembled at the University of Michigan's Center for Chemical Genomics | NA | NA | NA | 37 | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB000649 | 24239008 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Inhibition of chaperone activity | NA | YK5 | N-(6-amino-2-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}pyrimidin-4-yl)prop-2-enamide | COC1=NC(=NC(OC)=C1SC1=NC(N)=CC(NC(=O)C=C)=N1)N1CCN(C)CC1 | Structure based design | 90% inhibition at 100 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Refolding assay (luciferase) | NA | NA |
| HSPMDB000650 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 1 (Adenosine) | 2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol | NC1=NC=NC2=C1N=CN2C1OC(CO)C(O)C1O | Adenosine derivative | NA | 110 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000651 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 2 | 2-(6-amino-9H-purin-9-yl)-5-methyloxolane-3,4-diol | CC1OC(C(O)C1O)N1C=NC2=C1N=CN=C2N | Adenosine derivative | NA | 130 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000652 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 3 | 2-(6,8-diamino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol | NC1=NC2=C(N=CN=C2N)N1C1OC(CO)C(O)C1O | Adenosine derivative | NA | 7 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000653 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 4 | (2R,3R,4S,5R)-2-(6-Amino-8-(methylamino)-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol | CNc1nc2c(N)ncnc2n1[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O | Adenosine derivative | NA | 17 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000654 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 5 | (2R,3R,4S,5R)-2-(6-Amino-8-(dimethylamino)-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol | CN(C)c1nc2c(N)ncnc2n1[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O | Adenosine derivative | NA | >1000 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000655 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 6 | (2R,3R,4S,5R)-2-(6-Amino-8-methoxy-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol | COc1nc2c(N)ncnc2n1[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O | Adenosine derivative | NA | >1000 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000656 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 7 | (2R,3R,4S,5R)-2-(6-Amino-8-(methylamino)-9H-purin-9-yl)-5methyltetrahydrofuran-3,4-diol | CNc1nc2c(N)ncnc2n1[C@@H]3O[C@H](C)[C@@H](O)[C@H]3O | Adenosine derivative | NA | 27 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000657 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 8 | (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol | C1=CN(C2=C1C(=NC=N2)N)C3C(C(C(O3)CO)O)O | Adenosine derivative | NA | 28 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000658 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 9 | 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile | C1=C(C2=C(N1C3C(C(C(O3)CO)O)O)N=CN=C2N)C#N | Adenosine derivative | NA | 90 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000659 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 10 | 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboxamide | C1=C(C2=C(N1C3C(C(C(O3)CO)O)O)N=CN=C2N)C(=O)N | Adenosine derivative | NA | 3.3 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000660 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 12 | 4-Amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile | CNc1n([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c3ncnc(N)c3c1C#N | Adenosine derivative | NA | 3.3 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000661 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 13 | 4-Amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide | CNc1n([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c3ncnc(N)c3c1C(N)=O | Adenosine derivative | NA | 30 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000662 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 14 | 4-Amino-6-(benzylamino)-7-((2R,3R,4S,5R)-3,4-dihydroxy-5(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine5-carbonitrile | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccccc4)c(C#N)c12 | Adenosine derivative | NA | 2.8 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000663 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 15 | (2R,3R,4S,5R)-2-(6-Amino-8-(benzylamino)-9H-purin-9-yl)-5(hydroxymethyl)tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccccc4)nc12 | Adenosine derivative | NA | 1.5 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000664 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 17 | (2R,3R,4S,5R)-2-(6-Amino-8-((quinolin-6-ylmethyl)amino)-9Hpurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc5ncccc5c4)nc12 | Adenosine derivative | NA | 0.72 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000665 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 18 | (2R,3R,4S,5R)-2-(6-Amino-8-((4-chlorobenzyl)amino)-9H-purin-9yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)cc4)nc12 | Adenosine derivative | NA | 0.28 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000666 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 19 | (2R,3R,4S,5R)-2-(6-Amino-8-((4-?uorobenzyl)amino)-9H-purin-9yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(F)cc4)nc12 | Adenosine derivative | NA | 0.46 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000667 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 20 | (2R,3R,4S,5R)-2-(6-Amino-8-((4-methylbenzyl)amino)-9H-purin9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | Cc1ccc(CNc2nc3c(N)ncnc3n2[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)cc1 | Adenosine derivative | NA | 0.3 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000668 | 27119979 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | Binding affinity | NA | 21 | (2R,3R,4S,5R)-2-(6-Amino-8-((3,4-dichlorobenzyl)amino)-9Hpurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | Nc1ncnc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(NCc4ccc(Cl)c(Cl)c4)nc12 | Adenosine derivative | NA | 3.5 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB000669 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | JG-98 | 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.71 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000670 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | 3-benzyl-2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Br)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.44 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000671 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 3-benzyl-2-((Z)-((E)-5-(5-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(Br)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.27 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000672 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-nitrobenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)[N+]([O-])=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000673 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(methylsulfonyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(cc5N4C)[S](C)(=O)=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000674 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)C(F)(F)F | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.53 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000675 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC(F)(F)F)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.26 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000676 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC(F)(F)F)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000677 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | 3-benzyl-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(C)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.21 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000678 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9(JG-194) | 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.16 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000679 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | 3-benzyl-2-((Z)-((E)-5-(3,4-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cccc(C)c5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.25 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000680 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | 3-benzyl-2-((Z)-((E)-5-(3,7-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5c(C)cccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.29 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000681 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.08 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000682 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazo lidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.37 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000683 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.13 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000684 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(SC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.13 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000685 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | 2-((Z)-((E)-3-allyl-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-benzylthiazol-3-ium chloride | [Cl-].CN1C(\Sc2cc(Cl)ccc12)=C3/SC(=C\c4scc[n+]4Cc5ccccc5)/N(CC=C)C3=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.17 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000686 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-cyclopropyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CN1C(/Sc2cc(Cl)ccc12)=C3\S\C(=C/c4scc[n+]4Cc5ccccc5)N(C6CC6)C3=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.33 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000687 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-(3-methoxy-3-oxopropyl)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].COC(=O)CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.66 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000688 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-fluorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.16 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000689 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(3-fluorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(F)c3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.48 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000690 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-fluorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(F)cc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.61 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000691 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-chlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3Cl)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.19 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000692 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(3-chlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.26 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000693 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-chlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(Cl)cc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.45 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000694 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethyl)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.13 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000695 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | 3-(2-bromobenzyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Br)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.19 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000696 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.17 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000697 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methylbenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.19 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000698 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000699 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-((trifluoromethyl)thio)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3SC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.13 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000700 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.22 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000701 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32(JG-258) | 3-benzyl-2-((Z)-((E)-3'-ethyl-3-methyl-4'-oxo-3',4,4',5-tetrahydro-2'H,3H-[2,5'-bithiazolylidene]- 2'-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/SCCN4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000702 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | JG-98 | 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.39 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000703 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | 3-benzyl-2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Br)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.33 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000704 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 3-benzyl-2-((Z)-((E)-5-(5-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(Br)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.11 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000705 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-nitrobenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)[N+]([O-])=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 4.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000706 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(methylsulfonyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(cc5N4C)[S](C)(=O)=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >20 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000707 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)C(F)(F)F | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.36 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000708 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC(F)(F)F)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000709 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC(F)(F)F)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000710 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | 3-benzyl-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(C)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.078 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000711 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9(JG-194) | 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.15 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000712 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | 3-benzyl-2-((Z)-((E)-5-(3,4-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cccc(C)c5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.21 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000713 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | 3-benzyl-2-((Z)-((E)-5-(3,7-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5c(C)cccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.25 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000714 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.14 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000715 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazo lidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.36 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000716 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.16 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000717 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(SC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.12 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000718 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | 2-((Z)-((E)-3-allyl-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-benzylthiazol-3-ium chloride | [Cl-].CN1C(\Sc2cc(Cl)ccc12)=C3/SC(=C\c4scc[n+]4Cc5ccccc5)/N(CC=C)C3=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000719 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-cyclopropyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CN1C(/Sc2cc(Cl)ccc12)=C3\S\C(=C/c4scc[n+]4Cc5ccccc5)N(C6CC6)C3=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.56 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000720 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-(3-methoxy-3-oxopropyl)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].COC(=O)CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.24 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000721 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-fluorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.29 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000722 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(3-fluorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(F)c3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000723 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-fluorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(F)cc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000724 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-chlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3Cl)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.18 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000725 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(3-chlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.51 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000726 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-chlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(Cl)cc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.41 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000727 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethyl)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.13 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000728 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | 3-(2-bromobenzyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Br)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000729 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.17 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000730 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methylbenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000731 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.12 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000732 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-((trifluoromethyl)thio)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3SC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.16 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000733 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.12 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000734 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32(JG-258) | 3-benzyl-2-((Z)-((E)-3'-ethyl-3-methyl-4'-oxo-3',4,4',5-tetrahydro-2'H,3H-[2,5'-bithiazolylidene]- 2'-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/SCCN4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >20 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000735 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | JG-98 | 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 4.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000736 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | 3-benzyl-2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Br)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 6.1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000737 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 3-benzyl-2-((Z)-((E)-5-(5-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(Br)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.66 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000738 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-nitrobenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)[N+]([O-])=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000739 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(methylsulfonyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(cc5N4C)[S](C)(=O)=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000740 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethyl)benzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(ccc5N4C)C(F)(F)F | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000741 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-5-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC(F)(F)F)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.34 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000742 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC(F)(F)F)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000743 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | 3-benzyl-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(C)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.3 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000744 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9(JG-194) | 3-benzyl-2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(C)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.9 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000745 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | 3-benzyl-2-((Z)-((E)-5-(3,4-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cccc(C)c5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.3 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000746 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | 3-benzyl-2-((Z)-((E)-5-(3,7-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5c(C)cccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000747 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000748 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazo lidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5ccc(OC)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000749 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000750 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(SC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000751 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | 2-((Z)-((E)-3-allyl-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-benzylthiazol-3-ium chloride | [Cl-].CN1C(\Sc2cc(Cl)ccc12)=C3/SC(=C\c4scc[n+]4Cc5ccccc5)/N(CC=C)C3=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000752 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-cyclopropyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CN1C(/Sc2cc(Cl)ccc12)=C3\S\C(=C/c4scc[n+]4Cc5ccccc5)N(C6CC6)C3=O | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 3.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000753 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | 3-benzyl-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-(3-methoxy-3-oxopropyl)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].COC(=O)CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 4.9 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000754 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-fluorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000755 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(3-fluorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(F)c3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000756 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-fluorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(F)cc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.9 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000757 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-chlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3Cl)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000758 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(3-chlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cccc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.69 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000759 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(4-chlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccc(Cl)cc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 3.1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000760 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethyl)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000761 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | 3-(2-bromobenzyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Br)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000762 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.9 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000763 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methylbenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3C)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000764 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000765 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-((trifluoromethyl)thio)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3SC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 3.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000766 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000767 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32(JG-258) | 3-benzyl-2-((Z)-((E)-3'-ethyl-3-methyl-4'-oxo-3',4,4',5-tetrahydro-2'H,3H-[2,5'-bithiazolylidene]- 2'-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3)=C4/SCCN4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >20 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000768 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 33 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2,6-dichlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(Cl)cccc3Cl)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.16 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000769 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 34 | 3-((2-bromopyridin-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(/S/C(C1=O)=C2/Sc3cc(Cl)ccc3N2C)=C/c4scc[n+]4Cc5cccnc5Br | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000770 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 35 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chloropyridin-4-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccnc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000771 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 36 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.21 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000772 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000773 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 38 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3occc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.81 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000774 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 39 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(thiophen-3-ylmethyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cscc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.73 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000775 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 40 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-(methoxycarbonyl)thiophen-3-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccsc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.16 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000776 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 41 | 3-((2-bromothiophen-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccsc3Br)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.52 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000777 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42(JG-231) | 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.12 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000778 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 43 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2,5-dimethylthiophen-3-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cc(C)sc3C)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.098 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000779 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-methylthiazol-4-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3csc(C)n3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.96 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000780 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chlorothiazol-5-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3sc(Cl)nc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000781 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 46 | 3-((2-acetamidothiazol-4-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3csc(NC(C)=O)n3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000782 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 47 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3,5-dimethylisoxazol-4-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(C)onc3C)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000783 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 33 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2,6-dichlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(Cl)cccc3Cl)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.16 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000784 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 34 | 3-((2-bromopyridin-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(/S/C(C1=O)=C2/Sc3cc(Cl)ccc3N2C)=C/c4scc[n+]4Cc5cccnc5Br | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000785 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 35 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chloropyridin-4-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccnc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 7.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000786 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 36 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.12 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000787 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.97 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000788 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 38 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3occc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.13 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000789 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 39 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(thiophen-3-ylmethyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cscc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.11 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000790 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 40 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-(methoxycarbonyl)thiophen-3-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccsc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.22 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000791 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 41 | 3-((2-bromothiophen-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccsc3Br)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000792 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42(JG-231) | 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.25 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000793 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 43 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2,5-dimethylthiophen-3-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cc(C)sc3C)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.08 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000794 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-methylthiazol-4-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3csc(C)n3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.74 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000795 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chlorothiazol-5-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3sc(Cl)nc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.3 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000796 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 46 | 3-((2-acetamidothiazol-4-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3csc(NC(C)=O)n3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >20 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000797 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 47 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3,5-dimethylisoxazol-4-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(C)onc3C)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 10 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000798 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 33 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(2,6-dichlorobenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(Cl)cccc3Cl)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000799 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 34 | 3-((2-bromopyridin-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(/S/C(C1=O)=C2/Sc3cc(Cl)ccc3N2C)=C/c4scc[n+]4Cc5cccnc5Br | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000800 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 35 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chloropyridin-4-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccnc(Cl)c3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | >5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000801 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 36 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 5.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000802 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000803 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 38 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3-(methoxycarbonyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3occc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000804 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 39 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-(thiophen-3-ylmethyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cscc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 4.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000805 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 40 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-(methoxycarbonyl)thiophen-3-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccsc3C(=O)OC)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 3.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000806 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 41 | 3-((2-bromothiophen-3-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccsc3Br)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.3 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000807 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42(JG-231) | 3-((5-bromothiophen-2-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3sc(Br)cc3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000808 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 43 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2,5-dimethylthiophen-3-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3cc(C)sc3C)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 4.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000809 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-methylthiazol-4-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3csc(C)n3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 4.9 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000810 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((2-chlorothiazol-5-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3sc(Cl)nc3)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 8.9 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000811 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 46 | 3-((2-acetamidothiazol-4-yl)methyl)-2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3csc(NC(C)=O)n3)=C4/Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 4.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000812 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 47 | 2-((Z)-((E)-5-(6-chloro-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((3,5-dimethylisoxazol-4-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3c(C)onc3C)=C/4Sc5cc(Cl)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 7.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000813 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 48 | 2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5ccc(C)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.089 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000814 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 49 | 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(C)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.064 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000815 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 50 | 2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5ccc(OC)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.16 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000816 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 51 | 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.07 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000817 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 52 | 2-((Z)-((E)-3-ethyl-5-(6-isopropyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(ccc5N4C)C(C)C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.09 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000818 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 53 | 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.048 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000819 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 54 | 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(SC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.15 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000820 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 55 | 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC)=C4\Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.076 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000821 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 56 | 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(C)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.071 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000822 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 57(JG-345) | 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.049 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000823 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 58 | 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5ccc(C)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.088 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000824 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 59 | 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.093 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000825 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 60(JG-294) | 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000826 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 61 | 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C4\Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.11 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000827 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 48 | 2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5ccc(C)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.18 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000828 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 49 | 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(C)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.077 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000829 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 50 | 2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5ccc(OC)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.16 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000830 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 51 | 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.053 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000831 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 52 | 2-((Z)-((E)-3-ethyl-5-(6-isopropyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(ccc5N4C)C(C)C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.21 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000832 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 53 | 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.033 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000833 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 54 | 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(SC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.13 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000834 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 55 | 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC)=C4\Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.062 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000835 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 56 | 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(C)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.082 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000836 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 57(JG-345) | 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.046 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000837 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 58 | 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5ccc(C)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.054 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000838 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 59 | 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000839 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 60(JG-294) | 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.18 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000840 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 61 | 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C4\Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000841 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 48 | 2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5ccc(C)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000842 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 49 | 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C/4Sc5cc(C)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.75 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000843 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 50 | 2-((Z)-((E)-3-ethyl-5-(5-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5ccc(OC)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 2.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000844 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 51 | 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000845 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 52 | 2-((Z)-((E)-3-ethyl-5-(6-isopropyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-(trifluoromethoxy)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC(F)(F)F)=C4\Sc5cc(ccc5N4C)C(C)C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.48 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000846 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 53 | 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)- 4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.66 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000847 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 54 | 3-(2-chlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(methylthio)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3ccccc3Cl)=C4/Sc5cc(SC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.75 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000848 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 55 | 2-((Z)-((E)-3-ethyl-5-(6-methoxy-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2- ylidene)methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3OC)=C4\Sc5cc(OC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.77 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000849 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 56 | 2-((Z)-((E)-5-(3,6-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene) methyl)-3-(2-methoxybenzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3ccccc3OC)=C/4Sc5cc(C)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.96 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000850 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 57(JG-345) | 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-(2-(methoxycarbonyl)benzyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3ccccc3C(=O)OC)=C4\Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000851 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 58 | 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-5-(3,5-dimethylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5ccc(C)cc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.55 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000852 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 59 | 3-(2,6-dichlorobenzyl)-2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4- oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride | [Cl-].CCN1C(=O)C(\S\C1=C/c2scc[n+]2Cc3c(Cl)cccc3Cl)=C4/Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 0.3 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000853 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 60(JG-294) | 2-((Z)-((E)-5-(6-bromo-3-methylbenzo[d]thiazol-2(3H)-ylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)/C(SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C/4Sc5cc(Br)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 3.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000854 | 29953808 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 61 | 2-((Z)-((E)-3-ethyl-5-(6-ethyl-3-methylbenzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)-3-((5-(trifluoromethyl)furan-2-yl)methyl)thiazol-3-ium chloride | [Cl-].CCN\1C(=O)C(/SC1=C\c2scc[n+]2Cc3oc(cc3)C(F)(F)F)=C4\Sc5cc(CC)ccc5N4C | Benzothiazole Rhodacyanines derivative | NA | NA | NA | NA | 1.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000855 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17a | N-(6-Amino-2-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 0.9 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000856 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17b | N-(6-Amino-2-((4,6-dimethoxy-2-morpholinopyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCOCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 12.5 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000857 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17c | N-(6-Amino-2-((4,6-dimethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 17.1 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000858 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20a | N-(6-Amino-2-((4,6-diethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 0.89 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000859 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20b | N-(6-Amino-2-((4,6-diethoxy-2-morpholinopyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCOCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 2.2 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000860 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20c | N-(6-Amino-2-((4,6-diethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 4.5 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000861 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27a | N-(2-((4,6-Dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 1.25 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000862 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27b | N-(2-((4,6-Dimethoxy-2-morpholinopyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCOCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 2 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000863 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27c | N-(2-((4,6-Dimethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCCCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 3.15 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000864 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27d | N-(2-((4,6-Dimethoxy-2-(pyrrolidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 46.1 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000865 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 4-(5-((4-Acrylamidopyrimidin-2-yl)thio)-4,6-dimethoxypyrimidin2-yl)-1-methylpiperazine 1-Oxide | COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CC[N+](C)([O-])CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | >100 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000866 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | N-(6-Amino-2-((2-amino-4,6-dimethoxypyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(N)nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 3.9 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000867 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 36a | N-(3-((4,6-Dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)phenyl)acrylamide | COc1nc(nc(OC)c1Sc2cccc(NC(=O)C=C)c2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 7.8 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000868 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | N-(3-((4,6-Dimethoxy-2-morpholinopyrimidin-5-yl)thio)phenyl)acrylamide | COc1nc(nc(OC)c1Sc2cccc(NC(=O)C=C)c2)N3CCOCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 46.5 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000869 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 43 | N-(2-((4,6-Dimethyl-2-morpholinopyrimidin-5-yl)thio)pyrimidin4-yl)acrylamide | Cc1nc(nc(C)c1Sc2nccc(NC(=O)C=C)n2)N3CCOCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 14.4 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000870 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44a | N-(6-Amino-2-(2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)-4,6- dimethoxypyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(CCOCCOCCOCCO)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 3.8 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000871 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45a | N-(6-Amino-2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-6-methoxy-2-(4- methylpiperazin-1-yl)pyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OCCOCCOCCOCCO)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 76.5 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000872 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17a | N-(6-Amino-2-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 0.8 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000873 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17c | N-(6-Amino-2-((4,6-dimethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 9 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000874 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20a | N-(6-Amino-2-((4,6-diethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 1.1 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000875 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20c | N-(6-Amino-2-((4,6-diethoxy-2-(piperidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | CCOc1nc(nc(OCC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCCCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 7 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000876 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27a | N-(2-((4,6-Dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 1.2 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000877 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27d | N-(2-((4,6-Dimethoxy-2-(pyrrolidin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nccc(NC(=O)C=C)n2)N3CCCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 5 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000878 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | N-(6-Amino-2-((2-amino-4,6-dimethoxypyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | COc1nc(N)nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 3.2 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000879 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | N-(3-((4,6-Dimethoxy-2-morpholinopyrimidin-5-yl)thio)phenyl)acrylamide | COc1nc(nc(OC)c1Sc2cccc(NC(=O)C=C)c2)N3CCOCC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 16.5 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000880 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42a | N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)acrylamide | CN1CCN(CC1)c2nc(C)c(Sc3nccc(NC(=O)C=C)n3)c(C)n2 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 1.8 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000881 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42c | N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)pyrimidin-4-yl)methacrylamide | CC1=NC(=NC(=C1SC1=NC=CC(=N1)NC(C(=C)C)=O)C)N1CCN(CC1)C | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 16.7 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000882 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44a | N-(6-Amino-2-(2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)-4,6- dimethoxypyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(CCOCCOCCOCCO)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 7.5 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000883 | 24548207 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45a | N-(6-Amino-2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)-6-methoxy-2-(4- methylpiperazin-1-yl)pyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide | COc1nc(nc(OCCOCCOCCOCCO)c1Sc2nc(N)cc(NC(=O)C=C)n2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 50 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000884 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1a | N-(6-amino-2-{[4,6-diethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}pyrimidin-4-yl)prop-2-enamide | CCOC1=NC(=NC(OCC)=C1SC1=NC(N)=CC(NC(=O)C=C)=N1)N1CCN(C)CC1 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 0.89 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000885 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3a | N-(6-Amino-2-((4,6-diethoxy-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)pyrimidin-4-yl)propionamide | NC1=CC(=NC(=N1)SC=1C(=NC(=NC1OCC)N1CCN(CC1)C)OCC)NC(CC)=O | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 51.4 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000886 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1b | N-(2-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}pyrimidin-4-yl)prop-2-enamide | COC1=NC(=NC(OC)=C1SC1=NC=CC(NC(=O)C=C)=N1)N1CCN(C)CC1 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 1.25 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000887 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1c | N-(3-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}phenyl)prop-2-enamide | COC1=NC(=NC(OC)=C1SC1=CC=CC(NC(=O)C=C)=C1)N1CCN(C)CC1 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 7.8 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000888 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4e | N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)pyrimidin-4-yl)cyclopropanecarboxamide | CC1=NC(=NC(=C1SC1=NC=CC(=N1)NC(=O)C1CC1)C)N1CCN(CC1)C | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 60.5 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000889 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7c | 2-cyclobutyl-N-(3-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}phenyl)acetamide | COC1=NC(=NC(OC)=C1SC1=CC=CC(NC(=O)CC2CCC2)=C1)N1CCN(C)CC1 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 47.2 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000890 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7e | N-(3-{[4,6-dimethoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]sulfanyl}phenyl)-2-phenylacetamide | COC1=NC(=NC(OC)=C1SC1=CC=CC(NC(=O)CC2=CC=CC=C2)=C1)N1CCN(C)CC1 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 8.1 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000891 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4d | N-(2-((4,6-Dimethyl-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)pyrimidin-4-yl)furan-2-carboxamide | CN1CCN(CC1)c2nc(C)c(Sc3nccc(NC(=O)c4occc4)n3)c(C)n2 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 30.3 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000892 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7f | 2-Amino-N-(3-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)acetamide | COc1nc(nc(OC)c1Sc2cccc(NC(=O)CN)c2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 22.5 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000893 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9 | N-(6-Amino-2-((4,6-dimethoxy-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)pyrimidin-4-yl)-3-(dimethylamino)propanamide | COc1nc(nc(OC)c1Sc2nc(N)cc(NC(=O)CCN(C)C)n2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 14.7 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000894 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7h | 2-Amino-N-(3-((4-methoxy-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)thio)phenyl)acetamide | COc1nc(ncc1Sc2cccc(NC(=O)CN)c2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 25.2 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000895 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14b | N-(2-((2-Methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)-pyrimidin-4-yl)cyclopropanecarboxamide | COc1nc(ccc1Sc2nccc(NC(=O)C3CC3)n2)N4CCN(C)CC4 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 58.5 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000896 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16b | N-(3-((2-Methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)-phenyl)cyclopropanecarboxamide | COc1nc(ccc1Sc2cccc(NC(=O)C3CC3)c2)N4CCN(C)CC4 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 36.4 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000897 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16c | N-(3-((2-Methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)-phenyl)benzamide | COc1nc(ccc1Sc2cccc(NC(=O)c3ccccc3)c2)N4CCN(C)CC4 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 4.7 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000898 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16d | 2-Amino-N-(3-((2-methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl)thio)phenyl)acetamide | COc1nc(ccc1Sc2cccc(NC(=O)CN)c2)N3CCN(C)CC3 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 19.1 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000899 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27a | N-(3-((4-(Benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)acetamide | CN1CCN(CC1)c2ncc(Sc3cccc(NC(C)=O)c3)c(OCc4ccccc4)n2 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 5.2 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000900 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27b | N-(3-((4-(Benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)benzamide | CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)c4ccccc4)c3)c(OCc5ccccc5)n2 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 3.1 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000901 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27c | 2-Amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)acetamide | CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)CN)c3)c(OCc4ccccc4)n2 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 2.3 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000902 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27d | 2-Amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)propanamide | CC(N)C(=O)Nc1cccc(Sc2cnc(nc2OCc3ccccc3)N4CCN(C)CC4)c1 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 4.8r | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000903 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27e | 2-Amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)-3-methylbutanamide | CC(C)C(N)C(=O)Nc1cccc(Sc2cnc(nc2OCc3ccccc3)N4CCN(C)CC4)c1 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 3.1 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000904 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27f | N-(3-((4-(Benzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-thio)phenyl)pyrrolidine-2-carboxamide | CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)C4CCCN4)c3)c(OCc5ccccc5)n2 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 2.9 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000905 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27g | 2-Amino-N-(3-((2-(4-methylpiperazin-1-yl)-4-phenylpyrimidin-5-yl)thio)phenyl)acetamide | CN1CCN(CC1)c2ncc(Sc3cccc(NC(=O)CN)c3)c(n2)c4ccccc4 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 20.8 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000906 | 24548239 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27h | 2-amino-N-(3-{[2-(4-methylpiperazin-1-yl)-4-[(pyridin-4-yl)methoxy]pyrimidin-5-yl]sulfanyl}phenyl)acetamide | CN1CCN(CC1)C1=NC=C(SC2=CC=CC(NC(=O)CN)=C2)C(OCC2=CC=NC=C2)=N1 | 2,5-Thiodipyrimidine and 5-(Phenylthio) pyrimidine acrylamide | NA | NA | NA | NA | NA | NA | NA | 10.7 | Nucleotide binding domain (allosteric site) | NA | NA | Alamar Blue viability assay |
| HSPMDB000907 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 (apoptozole) | 4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)benzamide | COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 7 | Nucleotide binding domain | NA | NA | Resazurin based viability assay |
| HSPMDB000908 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7a | 2-Phenyl-1H-phenanthro[9,10-d]imidazole | [nH]1c(nc2c1c3ccccc3c4ccccc24)c5ccccc5 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 7.6 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000909 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7b | 2-(4-Fluorophenyl)-1H-phenanthro[9,10-d]imidazole | Fc1ccc(cc1)c2[nH]c3c4ccccc4c5ccccc5c3n2 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 6.7 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000910 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7c | 2-(4-Methoxyphenyl)-1H-phenanthro[9,10-d]imidazole | COc1ccc(cc1)c2[nH]c3c4ccccc4c5ccccc5c3n2 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 3 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000911 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7d | 2-(3,5-Bis(trifluoromethyl)phenyl)-1H-phenanthro[9,10-d]imidazole | FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2[nH]c3c4ccccc4c5ccccc5c3n2 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 7.3 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000912 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | 6,9-Dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole | COc1ccc2c3[nH]c(nc3c4ccc(OC)cc4c2c1)c5ccccc5 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 7.8 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000913 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | 2-(3,5-Bis(trifluoromethyl)phenyl)-6,9-dimethoxy-1H-phenanthro[9,10-d]imidazole | COc1ccc2c3[nH]c(nc3c4ccc(OC)cc4c2c1)c5cc(cc(c5)C(F)(F)F)C(F)(F)F | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 11.2 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000914 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | 2-(4-Methoxyphenyl)-4,5-diphenyl-1H-imidazole | COc1ccc(cc1)c2[nH]c(c3ccccc3)c(n2)c4ccccc4 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >20 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000915 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | 2,4,5-Tri(4-methoxyphenyl)-1H-imidazole | COc1ccc(cc1)c2[nH]c(c3ccc(OC)cc3)c(n2)c4ccc(OC)cc4 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 7.8 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000916 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | 2,4,5-Tri(4-fluorophenyl)-1H-imidazole | Fc1ccc(cc1)c2[nH]c(c3ccc(F)cc3)c(n2)c4ccc(F)cc4 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 9.5 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000917 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | 1-Methyl-2-phenyl-1H-phenanthro[9,10-d]imidazole | Cn1c(nc2c3ccccc3c4ccccc4c12)c5ccccc5 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 9.4 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000918 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | 1-Benzyl-2-phenyl-1H-phenanthro[9,10-d]imidazole | C(n1c(nc2c3ccccc3c4ccccc4c12)c5ccccc5)c6ccccc6 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 6.8 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000919 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-phenanthro-[9,10-d]imidazole | FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4ccccc4c5ccccc5c3n2Cc6ccccc6 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >20 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000920 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 1-(4-Carboxamidobenzyl)-2-phenyl-1H-phenanthro[9,10-d]imidazole | NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=CC=C2)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >20 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000921 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 1-(4-Carboxamidobenzyl)-2-(4-fluorophenyl)-1H-phenanthro-[9,10-d]imidazole | NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=C(F)C=C2)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 5.9 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000922 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 1-(4-Carboxamidobenzyl)-2-(4-methoxyphenyl)-1H-phenanthro-[9,10-d]imidazole | COC1=CC=C(C=C1)C1=NC2=C(N1CC1=CC=C(C=C1)C(N)=O)C1=C(C=CC=C1)C1=C2C=CC=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 5.5 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000923 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-phenanthro[9,10-d]-imidazole | NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >20 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000924 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | 1-(4-Carboxamidobenzyl)-6,9-dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole | COC1=CC2=C(C=C1)C1=C(N(CC3=CC=C(C=C3)C(N)=O)C(=N1)C1=CC=CC=C1)C1=C2C=C(OC)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 3.4 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000925 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 2-Phenyl-1H-imidazo[4,5-f][1,10]phenanthroline | [nH]1c(nc2c1c3cccnc3c4ncccc24)c5ccccc5 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 0.09 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000926 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30 | 1-Methyl-2-phenyl-1H-imidazo[4,5-f ][1,10]phenanthroline | Cn1c(nc2c3cccnc3c4ncccc4c12)c5ccccc5 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 2.6 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000927 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f ]-[1,10]phenanthroline | FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4cccnc4c5ncccc5c3n2Cc6ccccc6 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 0.5 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000928 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32 | 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f][1,10]-phenanthroline | NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(N=CC=C2)C2=C3C=CC=N2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 0.7 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000929 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7a | 2-Phenyl-1H-phenanthro[9,10-d]imidazole | [nH]1c(nc2c1c3ccccc3c4ccccc24)c5ccccc5 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >5 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000930 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7c | 2-(4-Methoxyphenyl)-1H-phenanthro[9,10-d]imidazole | COc1ccc(cc1)c2[nH]c3c4ccccc4c5ccccc5c3n2 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 4 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000931 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | 2,4,5-Tri(4-fluorophenyl)-1H-imidazole | Fc1ccc(cc1)c2[nH]c(c3ccc(F)cc3)c(n2)c4ccc(F)cc4 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >10 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000932 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 1-(4-Carboxamidobenzyl)-2-(4-fluorophenyl)-1H-phenanthro-[9,10-d]imidazole | NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=C(F)C=C2)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >10 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000933 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 1-(4-Carboxamidobenzyl)-2-(4-methoxyphenyl)-1H-phenanthro-[9,10-d]imidazole | COC1=CC=C(C=C1)C1=NC2=C(N1CC1=CC=C(C=C1)C(N)=O)C1=C(C=CC=C1)C1=C2C=CC=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >10 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000934 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | 1-(4-Carboxamidobenzyl)-6,9-dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole | COC1=CC2=C(C=C1)C1=C(N(CC3=CC=C(C=C3)C(N)=O)C(=N1)C1=CC=CC=C1)C1=C2C=C(OC)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >10 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000935 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 2-Phenyl-1H-imidazo[4,5-f][1,10]phenanthroline | [nH]1c(nc2c1c3cccnc3c4ncccc24)c5ccccc5 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 0.69 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000936 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f ]-[1,10]phenanthroline | FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4cccnc4c5ncccc5c3n2Cc6ccccc6 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 2.8 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000937 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32 | 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f][1,10]-phenanthroline | NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(N=CC=C2)C2=C3C=CC=N2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 2.3 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000938 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 1-(4-Carboxamidobenzyl)-2-(4-fluorophenyl)-1H-phenanthro-[9,10-d]imidazole | NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(C=CC=C2)C2=C3C=CC=C2)C2=CC=C(F)C=C2)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >5 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000939 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 1-(4-Carboxamidobenzyl)-2-(4-methoxyphenyl)-1H-phenanthro-[9,10-d]imidazole | COC1=CC=C(C=C1)C1=NC2=C(N1CC1=CC=C(C=C1)C(N)=O)C1=C(C=CC=C1)C1=C2C=CC=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >5 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000940 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | 1-(4-Carboxamidobenzyl)-6,9-dimethoxy-2-phenyl-1H-phenanthro[9,10-d]imidazole | COC1=CC2=C(C=C1)C1=C(N(CC3=CC=C(C=C3)C(N)=O)C(=N1)C1=CC=CC=C1)C1=C2C=C(OC)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | >5 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000941 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 2-Phenyl-1H-imidazo[4,5-f][1,10]phenanthroline | [nH]1c(nc2c1c3cccnc3c4ncccc24)c5ccccc5 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 0.32 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000942 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 1-Benzyl-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f ]-[1,10]phenanthroline | FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2nc3c4cccnc4c5ncccc5c3n2Cc6ccccc6 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 2.9 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000943 | 27035072 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32 | 1-(4-Carboxamidobenzyl)-2-(3,5-bis(trifluoromethyl)phenyl)-1H-imidazo[4,5-f][1,10]-phenanthroline | NC(=O)C1=CC=C(CN2C(=NC3=C2C2=C(N=CC=C2)C2=C3C=CC=N2)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C=C1 | Phenanthro[9,10-d]imidazoles and imidazo[4,5-f][1,10]phenanthroline | NA | NA | NA | NA | NA | NA | NA | 2.5 | NA | NA | NA | Resazurin based viability assay |
| HSPMDB000944 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | MKT-077 | 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 | Rhodacyanine | NA | NA | NA | NA | 1.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000945 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-01 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000946 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | 2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000947 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 7.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000948 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | 2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 5.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000949 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 6.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000950 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 3.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000951 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](CC)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 13 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000952 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 8.3 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000953 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 2.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000954 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9 | 2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 4.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000955 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | 2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 4.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000956 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | 2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 8.3 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000957 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | 2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 4.1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000958 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | 2-{[(2Z)-3-ethyl-5-[(2E)-5-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(OC)C=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 2.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000959 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | 2-{[(2Z)-3-ethyl-5-[(2E)-6-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(OC)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000960 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-5-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(C=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 21 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000961 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-6-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(=CC=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 19 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000962 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | 1-methyl-2-{[(2Z)-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-3-(prop-2-en-1-yl)-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC=C)C1=O | Rhodacyanine derivative | NA | NA | NA | NA | 3.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000963 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | 2-{[(2Z)-3-benzyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC2=CC=CC=C2)C1=O | Rhodacyanine derivative | NA | NA | NA | NA | 1.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000964 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-propylpyridin-1-ium chloride | [Cl-].CCC[N+]1=C(\C=C2/S\C(C(=O)N2CC)=C2\SC3=CC=CC=C3N2C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 1.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000965 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | 1-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000966 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-(2-hydroxyethyl)pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CCO)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 24 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000967 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 4-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=CC=[N+](C)C=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 1.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000968 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyrimidin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=N1 | Rhodacyanine derivative | NA | NA | NA | NA | 5.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000969 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-3-methyl-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 5.1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000970 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | 3-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 2.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000971 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000972 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27(JG-83) | 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000973 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28(JG-84) | 3-benzyl-2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000974 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 3-benzyl-2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000975 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30(JG-98) | 3-benzyl-2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000976 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 3-benzyl-2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000977 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | MKT-077 | 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 2.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000978 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | YM-01 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 5.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000979 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | 2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 2.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000980 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 18 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000981 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | 2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 6.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000982 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 8.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000983 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000984 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-5-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(F)C=C2N1C)=C\C1=[N+](CC)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 2.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000985 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-6-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(F)=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.9 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000986 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | 1-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-7-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(F)C=CC=C2N1C)=C\C1=[N+](CC)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000987 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9 | 2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 7.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000988 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | 2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 28 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000989 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | 2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 9.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000990 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | 2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 5.2 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000991 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | 2-{[(2Z)-3-ethyl-5-[(2E)-5-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(OC)C=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 14 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000992 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | 2-{[(2Z)-3-ethyl-5-[(2E)-6-methoxy-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(OC)=CC=C2N1C)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 11 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000993 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-5-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(C=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000994 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-6-(trifluoromethyl)-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(=CC=C2N1C)C(F)(F)F)=C\C1=[N+](C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | >30 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000995 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | 1-methyl-2-{[(2Z)-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-3-(prop-2-en-1-yl)-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC=C)C1=O | Rhodacyanine derivative | NA | NA | NA | NA | 8.4 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000996 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | 2-{[(2Z)-3-benzyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CN1\C(SC2=CC=CC=C12)=C1/S\C(=C/C2=[N+](C)C=CC=C2)N(CC2=CC=CC=C2)C1=O | Rhodacyanine derivative | NA | NA | NA | NA | 2.9 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000997 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-propylpyridin-1-ium chloride | [Cl-].CCC[N+]1=C(\C=C2/S\C(C(=O)N2CC)=C2\SC3=CC=CC=C3N2C)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 2.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000998 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | 1-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 1.5 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB000999 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-(2-hydroxyethyl)pyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CCO)C=CC=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 6.9 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001000 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 4-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyridin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=CC=[N+](C)C=C1 | Rhodacyanine derivative | NA | NA | NA | NA | 19 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001001 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1-methylpyrimidin-1-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CC=N1 | Rhodacyanine derivative | NA | NA | NA | NA | 9.1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001002 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-3-methyl-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](C)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001003 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | 3-ethyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001004 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.6 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001005 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27(JG-83) | 3-benzyl-2-{[(2Z)-3-ethyl-5-[(2E)-4-fluoro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(F)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001006 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28(JG-84) | 3-benzyl-2-{[(2Z)-5-[(2E)-4-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=CC(Cl)=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001007 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 3-benzyl-2-{[(2Z)-5-[(2E)-5-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC=C(Cl)C=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.8 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001008 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30(JG-98) | 3-benzyl-2-{[(2Z)-5-[(2E)-6-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=CC(Cl)=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 0.7 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001009 | 24312699 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 3-benzyl-2-{[(2Z)-5-[(2E)-7-chloro-3-methyl-2,3-dihydro-1,3-benzothiazol-2-ylidene]-3-ethyl-4-oxo-1,3-thiazolidin-2-ylidene]methyl}-1,3-thiazol-3-ium chloride | [Cl-].CCN1\C(S\C(C1=O)=C1\SC2=C(Cl)C=CC=C2N1C)=C\C1=[N+](CC2=CC=CC=C2)C=CS1 | Rhodacyanine derivative | NA | NA | NA | NA | 1 | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | NA | MTT viability assay |
| HSPMDB001010 | 25148104 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2-phenylethyenesulfonamide (PES) | 2-phenylethynesulfonamide | C1=CC=C(C=C1)C#CS(=O)(=O)N | NA | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | 90% at 10 uM | MTT viability assay |
| HSPMDB001011 | 25148104 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | PET-16 | triphenyl(phenylethynyl)phosphonium bromide | [Br-].C1(=CC=CC=C1)[P+](C#CC1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 | 2-phenylethyenesulfonamide (PES) derivative | NA | NA | NA | NA | NA | NA | NA | NA | C-terminal domain | NA | 100% at 10 um | MTT viability assay |
| HSPMDB001012 | 25148104 | Hsp70 | Hsp72 (HSPA1A) | Human | Cytosol and nucleus | Binding affinity | NA | 2-phenylethyenesulfonamide (PES) | 2-phenylethynesulfonamide | C1=CC=C(C=C1)C#CS(=O)(=O)N | NA | NA | 5.7 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB001013 | 25148104 | Hsp70 | Hsp72 (HSPA1A) | Human | Cytosol and nucleus | Binding affinity | NA | PET-16 | triphenyl(phenylethynyl)phosphonium bromide | [Br-].C1(=CC=CC=C1)[P+](C#CC1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 | 2-phenylethyenesulfonamide (PES) derivative | NA | 3.8 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB001014 | 25148104 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | PES | 2-phenylethynesulfonamide | C1=CC=C(C=C1)C#CS(=O)(=O)N | NA | NA | 6.8 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB001015 | 25148104 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Binding affinity | NA | PET-16 | triphenyl(phenylethynyl)phosphonium bromide | [Br-].C1(=CC=CC=C1)[P+](C#CC1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 | 2-phenylethyenesulfonamide (PES) derivative | NA | 6 | NA | NA | NA | NA | NA | NA | C-terminal domain | Isothermal Titration Calorimetry (ITC) | NA | NA |
| HSPMDB001016 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Lapatinib | 2-phenylethynesulfonamide | C1=CC=C(C=C1)C#CS(=O)(=O)N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 75.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001017 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 14.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001018 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 17.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001019 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 62.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001020 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 61.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001021 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 54.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001022 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 10.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001023 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 36.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001024 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 70.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001025 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9 | N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 38.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001026 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001027 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 15.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001028 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 68.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001029 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 26.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001030 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 44.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001031 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 54.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001032 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 62.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001033 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 49.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001034 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 54.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001035 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 70 at 5 uM | Luminescence based viability assay |
| HSPMDB001036 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 42.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001037 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | -4.1 | Luminescence based viability assay |
| HSPMDB001038 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 69.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001039 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 7.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001040 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 45.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001041 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 7.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001042 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 10.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001043 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 64.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001044 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine | CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 1.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001045 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 14.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001046 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 2.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001047 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 70 at 5 uM | Luminescence based viability assay |
| HSPMDB001048 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 11 at 5 uM | Luminescence based viability assay |
| HSPMDB001049 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 33 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine | Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 70 at 5 uM | Luminescence based viability assay |
| HSPMDB001050 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 34 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 3.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001051 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 35 | N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 40.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001052 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 36 | 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | 1.41 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 75.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001053 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | 1.04 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 75.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001054 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 38 | N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 39.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001055 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 39 | N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 35.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001056 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 40 | N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl | Piperidine derivative | NA | NA | NA | 1.62 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 74.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001057 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 41 | 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 74.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001058 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42 | N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 69.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001059 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 47 | N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 36.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001060 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44 | N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 61 at 5 uM | Luminescence based viability assay |
| HSPMDB001061 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45 | N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 67.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001062 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 46 | N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | 1.99 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 21.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001063 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 43 | N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | 0.78 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 73.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001064 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 48 | 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 60.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001065 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 49 | 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 71.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001066 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 50 | 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 61.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001067 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 51 | N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 27.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001068 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 52 | N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 52.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001069 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 53 | N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 65.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001070 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 54 | N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 36.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001071 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 55 | N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001072 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 56 | N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001073 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 57 | N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 27.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001074 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 58 | 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5 at 5 uM | Luminescence based viability assay |
| HSPMDB001075 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 59 | N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 53.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001076 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 60 | N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001077 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 61 | N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 7.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001078 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 62 | N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 11.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001079 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 63 | N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 45.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001080 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 64 | 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 65.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001081 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 65 | 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 25.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001082 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 66 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 45.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001083 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 67 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001084 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Lapatinib | N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine | CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 18 at 5 uM | Luminescence based viability assay |
| HSPMDB001085 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001086 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 19.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001087 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 67.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001088 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 66.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001089 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 50.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001090 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 13.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001091 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 20.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001092 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 65.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001093 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9 | N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 25.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001094 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001095 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 1.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001096 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 66.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001097 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 19.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001098 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 36.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001099 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 50.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001100 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 67.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001101 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 59.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001102 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 54.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001103 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 66.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001104 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 34.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001105 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 4 at 5 uM | Luminescence based viability assay |
| HSPMDB001106 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 68.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001107 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9 at 5 uM | Luminescence based viability assay |
| HSPMDB001108 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 53.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001109 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 8.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001110 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 3.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001111 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 61.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001112 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine | CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 4 at 5 uM | Luminescence based viability assay |
| HSPMDB001113 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 16 at 5 uM | Luminescence based viability assay |
| HSPMDB001114 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001115 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 66.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001116 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 10.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001117 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 33 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine | Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 66.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001118 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 34 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 7.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001119 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 35 | N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 44.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001120 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 36 | 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | 1.47 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 76.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001121 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | 0.94 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 70.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001122 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 38 | N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 29.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001123 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 39 | N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 25.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001124 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 40 | N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl | Piperidine derivative | NA | NA | NA | 1.68 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 68.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001125 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 41 | 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 68.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001126 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42 | N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 65.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001127 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 47 | N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 28.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001128 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44 | N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 56.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001129 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45 | N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 63.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001130 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 46 | N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | 1.7 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 17.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001131 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 43 | N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | 0.7 | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 70 at 5 uM | Luminescence based viability assay |
| HSPMDB001132 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 48 | 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 58.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001133 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 49 | 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 72.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001134 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 50 | 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 58.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001135 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 51 | N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 22.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001136 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 52 | N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 35.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001137 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 53 | N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 62.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001138 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 54 | N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 26.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001139 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 55 | N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 10.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001140 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 56 | N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 14.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001141 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 57 | N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 18.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001142 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 58 | 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 8 at 5 uM | Luminescence based viability assay |
| HSPMDB001143 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 59 | N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 52.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001144 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 60 | N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001145 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 61 | N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 8.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001146 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 62 | N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001147 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 63 | N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 48.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001148 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 64 | 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 62.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001149 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 65 | 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 16.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001150 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 66 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 32.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001151 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 67 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001152 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Lapatinib | N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine | CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 40.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001153 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 14.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001154 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001155 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 35.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001156 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 51.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001157 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 32.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001158 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 33.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001159 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 24.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001160 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 49.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001161 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9 | N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 24.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001162 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 25.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001163 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 31.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001164 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 38.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001165 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 31.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001166 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 31.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001167 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 32.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001168 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 42.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001169 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 47.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001170 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 45.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001171 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 36.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001172 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 25.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001173 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | -8.5 | Luminescence based viability assay |
| HSPMDB001174 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 35.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001175 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | -1.3 | Luminescence based viability assay |
| HSPMDB001176 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 42.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001177 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001178 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 10.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001179 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 30.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001180 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine | CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 4.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001181 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 10.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001182 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 3.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001183 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 36.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001184 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 13.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001185 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 33 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine | Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 36.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001186 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 34 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 3.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001187 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 35 | N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 46 at 5 uM | Luminescence based viability assay |
| HSPMDB001188 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 36 | 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 46.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001189 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 55.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001190 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 38 | N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 29.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001191 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 39 | N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 39.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001192 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 40 | N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 64.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001193 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 41 | 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 64.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001194 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42 | N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 55.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001195 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 47 | N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 45.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001196 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44 | N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 45.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001197 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45 | N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 50.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001198 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 46 | N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 36.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001199 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 43 | N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 53.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001200 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 48 | 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 27.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001201 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 49 | 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 53.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001202 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 50 | 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 30.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001203 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 51 | N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 22 at 5 uM | Luminescence based viability assay |
| HSPMDB001204 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 52 | N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 41.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001205 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 53 | N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 48.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001206 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 54 | N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 23.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001207 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 55 | N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 8.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001208 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 56 | N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001209 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 57 | N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 20.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001210 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 58 | 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 10.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001211 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 59 | N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 30.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001212 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 60 | N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 6.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001213 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 61 | N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 4.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001214 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 62 | N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 25.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001215 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 63 | N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 39.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001216 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 64 | 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 42.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001217 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 65 | 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 20.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001218 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 66 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 27.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001219 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 67 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 8.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001220 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Lapatinib | N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine | CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 79 at 5 uM | Luminescence based viability assay |
| HSPMDB001221 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 16.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001222 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 13.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001223 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 41.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001224 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 45.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001225 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 40.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001226 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001227 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 26 at 5 uM | Luminescence based viability assay |
| HSPMDB001228 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 41.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001229 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9 | N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 17.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001230 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001231 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 21.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001232 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 49.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001233 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 19.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001234 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 26.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001235 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 40.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001236 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 42.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001237 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001238 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 24.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001239 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 37.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001240 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 23.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001241 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 7.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001242 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 41.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001243 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 18.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001244 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 34.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001245 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 15.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001246 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001247 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 47.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001248 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine | CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001249 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 26.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001250 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 4.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001251 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 37.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001252 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 26.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001253 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 33 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine | Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 37.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001254 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 34 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 17.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001255 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 35 | N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 31.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001256 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 36 | 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 83.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001257 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 78.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001258 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 38 | N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 30.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001259 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 39 | N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 26.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001260 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 40 | N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 87.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001261 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 41 | 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 87.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001262 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42 | N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 38.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001263 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 47 | N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 41.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001264 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44 | N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 19.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001265 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45 | N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 32.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001266 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 46 | N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 22.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001267 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 43 | N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 85.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001268 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 48 | 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 31.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001269 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 49 | 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 86.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001270 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 50 | 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 19.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001271 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 51 | N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 24.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001272 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 52 | N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 27.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001273 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 53 | N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 27.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001274 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 54 | N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 18.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001275 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 55 | N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001276 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 56 | N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 14.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001277 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 57 | N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 13.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001278 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 58 | 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 20.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001279 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 59 | N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 22.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001280 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 60 | N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 16.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001281 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 61 | N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 7.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001282 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 62 | N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001283 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 63 | N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 15.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001284 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 64 | 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 23.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001285 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 65 | 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 17.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001286 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 66 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 29.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001287 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 67 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001288 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Lapatinib | N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine | CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 10.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001289 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001290 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 7.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001291 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 13.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001292 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 6.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001293 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 11.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001294 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 0.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001295 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 25.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001296 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12 at 5 uM | Luminescence based viability assay |
| HSPMDB001297 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9 | N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001298 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001299 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 6.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001300 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001301 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 2.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001302 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 7.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001303 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 11.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001304 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 10.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001305 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 4.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001306 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 26.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001307 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 40.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001308 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 11.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001309 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 4.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001310 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 7.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001311 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | -0.1 | Luminescence based viability assay |
| HSPMDB001312 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001313 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 8.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001314 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 1.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001315 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 11.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001316 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine | CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001317 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 8.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001318 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 1.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001319 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 40.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001320 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 25.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001321 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 33 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine | Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 40.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001322 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 34 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 4.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001323 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 35 | N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 30.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001324 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 36 | 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 86.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001325 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 78.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001326 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 38 | N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001327 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 39 | N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 24.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001328 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 40 | N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 80.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001329 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 41 | 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 80.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001330 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42 | N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 42 at 5 uM | Luminescence based viability assay |
| HSPMDB001331 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 47 | N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 35.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001332 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44 | N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 29.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001333 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45 | N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 35.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001334 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 46 | N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 34.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001335 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 43 | N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 71 at 5 uM | Luminescence based viability assay |
| HSPMDB001336 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 48 | 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 16.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001337 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 49 | 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 74.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001338 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 50 | 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 13.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001339 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 51 | N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 11.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001340 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 52 | N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 16.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001341 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 53 | N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 17.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001342 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 54 | N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 15.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001343 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 55 | N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 3.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001344 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 56 | N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9 at 5 uM | Luminescence based viability assay |
| HSPMDB001345 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 57 | N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 29 at 5 uM | Luminescence based viability assay |
| HSPMDB001346 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 58 | 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 22 at 5 uM | Luminescence based viability assay |
| HSPMDB001347 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 59 | N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 19.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001348 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 60 | N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 28 at 5 uM | Luminescence based viability assay |
| HSPMDB001349 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 61 | N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001350 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 62 | N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 24.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001351 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 63 | N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 16.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001352 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 64 | 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 16.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001353 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 65 | 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 8.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001354 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 66 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001355 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 67 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 30.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001356 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Lapatinib | N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine | CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 42.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001357 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 1 | N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 41.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001358 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 2 | 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 43.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001359 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 3 | N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 71.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001360 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 4 | 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 70.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001361 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 5 | N-(2-chloro-6-fluorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 67.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001362 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 6 | N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 36.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001363 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 7 | 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 52.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001364 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 8 | N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 71.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001365 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 9 | N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 51.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001366 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 10 | N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 23.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001367 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 11 | N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccccc3C)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 35.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001368 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 12 | N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 67.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001369 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 13 | N-(3-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(F)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 44.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001370 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 14 | N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 62.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001371 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 15 | N-(4-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(F)cc3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 67.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001372 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 16 | N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 69.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001373 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 17 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl) piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(F)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 65.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001374 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 18 | N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 63.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001375 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 19 | N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 72.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001376 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 20 | N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 59.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001377 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 21 | 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccccc1C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 8.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001378 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 22 | 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 68.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001379 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 23 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(F)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 11 at 5 uM | Luminescence based viability assay |
| HSPMDB001380 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 24 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)c(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 63.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001381 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 25 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(Cl)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001382 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 26 | N-(2-chloro-6-fluorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CN(Cc1c(F)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 22.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001383 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 27 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1ccc(Cl)cc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 60.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001384 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 28 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-methylbenzyl)piperidin-4-amine | CN(Cc1ccccc1C)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 3.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001385 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 29 | 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | CN(Cc1ccc(C)cc1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 29.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001386 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 30 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-fluorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1cccc(F)c1)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 4.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001387 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 31 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-methylpiperidin-4-amine | CN(Cc1c(Cl)cccc1Cl)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 72.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001388 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 32 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 32.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001389 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 33 | 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-fluorobenzyl)piperidin-4-amine | Fc1ccc(CNC2CCN(CC2)Cc3sc(Cl)nc3)cc1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 72.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001390 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 34 | N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piperidin-4-amine | Clc1sc(CN2CCC(CC2)NCc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 2.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001391 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 35 | N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 82.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001392 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 36 | 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 82.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001393 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 37 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 84.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001394 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 38 | N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 60 at 5 uM | Luminescence based viability assay |
| HSPMDB001395 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 39 | N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 65.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001396 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 40 | N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 68.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001397 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 41 | 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 68.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001398 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 42 | N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 66.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001399 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 47 | N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 60.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001400 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 44 | N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 69.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001401 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 45 | N-(3-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 66.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001402 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 46 | N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 45.3 at 5 uM | Luminescence based viability assay |
| HSPMDB001403 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 43 | N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 79.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001404 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 48 | 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 66.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001405 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 49 | 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 79.5 at 5 uM | Luminescence based viability assay |
| HSPMDB001406 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 50 | 1-(2-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 68.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001407 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 51 | N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 50.6 at 5 uM | Luminescence based viability assay |
| HSPMDB001408 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 52 | N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 60.2 at 5 uM | Luminescence based viability assay |
| HSPMDB001409 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 53 | N-(2-chloro-6-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 64.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001410 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 54 | N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 56.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001411 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 55 | N-(3-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3cccc(F)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 27.9 at 5 uM | Luminescence based viability assay |
| HSPMDB001412 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 56 | N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 40.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001413 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 57 | N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 46.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001414 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 58 | 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)piperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(C)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 13.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001415 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 59 | N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 65.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001416 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 60 | N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 12.7 at 5 uM | Luminescence based viability assay |
| HSPMDB001417 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 61 | N-(4-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 5 at 5 uM | Luminescence based viability assay |
| HSPMDB001418 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 62 | N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cccc(Cl)c3 | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 23.8 at 5 uM | Luminescence based viability assay |
| HSPMDB001419 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 63 | N-(2-chloro-6-fluorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 59.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001420 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 64 | 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 66.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001421 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 65 | 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 46.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001422 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 66 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 61.1 at 5 uM | Luminescence based viability assay |
| HSPMDB001423 | 25935385 | Hsp70 | Hsc70 (HSPA8) and Hsp72 (HSPA1A) | Human | Cytosol and nucleus | NA | Antiproliferative activity | 67 | N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1cc(ncn1)N2CCC(CC2)N(C)Cc3cc(Cl)ccc3Cl | Piperidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | NA | 9.4 at 5 uM | Luminescence based viability assay |
| HSPMDB001424 | 25935385 | Hsp70 | Hsp70 | Human | Cytosol | Binding affinity | NA | VER-155008 | 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile | Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc5ccc(Cl)c(Cl)c5)nc12 | Piperidine derivative | NA | 0.206 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB001425 | 25935385 | Hsp70 | Hsp70 | Human | Cytosol | Binding affinity | NA | 12 | N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 | Piperidine derivative | NA | 0.1999 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB001426 | 25935385 | Hsp70 | Hsp70 | Human | Cytosol | Binding affinity | NA | 14 | N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3cccc(Cl)c3)cn1 | Piperidine derivative | NA | 2.454 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB001427 | 25935385 | Hsp70 | Hsp70 | Human | Cytosol | Binding affinity | NA | 35 | N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | 2.045 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB001428 | 25935385 | Hsp70 | Hsp70 | Human | Cytosol | Binding affinity | NA | 36 | 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | NA | 0.2463 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB001429 | 25935385 | Hsp70 | Hsp70 | Human | Cytosol | Binding affinity | NA | 56 | N-(4-fluorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | NA | 2.811 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | Surface plasmon resonance (SPR) | NA | NA |
| HSPMDB001430 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 4 | 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(cc3)C#N)cn1 | Piperidine derivative | 5.49% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001431 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 8 | N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-methylpiperidin-4-amine | CCOc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | 4.5% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001432 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 12 | N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(C)cc3)cn1 | Piperidine derivative | 10.59% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001433 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 16 | N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)c(Cl)c3)cn1 | Piperidine derivative | 10.74% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001434 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 19 | N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-yl)methyl)piperidin-4-amine | CSc1sc(CN2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl)cn1 | Piperidine derivative | 6.21% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001435 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 22 | 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)amino)methyl) benzonitrile | CN(Cc1ccc(cc1)C#N)C2CCN(CC2)Cc3sc(Cl)nc3 | Piperidine derivative | 11.28% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001436 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 35 | N-(4-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(F)cc3 | Piperidine derivative | 7.73% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001437 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 36 | 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(cc3)C#N | Piperidine derivative | 8.14% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001438 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 37 | N-(2-chloro-6-fluorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(F)cccc3Cl | Piperidine derivative | 20.39% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001439 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 40 | N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccc(Cl)cc3Cl | Piperidine derivative | 8.28% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001440 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 41 | 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)amino)methyl) benzonitrile | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3C#N | Piperidine derivative | 16.67% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001441 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 43 | N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3c(Cl)cccc3Cl | Piperidine derivative | 12.81% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001442 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 46 | N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-amine | CSc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | 11.63% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001443 | 25935385 | Hsp70 | DnaK:DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity | NA | 47 | N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-methylpiperidin-4-amine | COc1nccc(n1)N2CCC(CC2)N(C)Cc3ccccc3Cl | Piperidine derivative | 6.11% at 200 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain (allosteric site) | ATPase assay | NA | NA |
| HSPMDB001444 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F | Piperidine derivative | NA | NA | NA | 2.8 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001445 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-GA | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 0.73 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001446 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 0.74 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001447 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-amide-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001448 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-Imatinib | 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001449 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O4-Imatinib | 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001450 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F | Imidazole derivative | NA | NA | NA | 3.3 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001451 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-GA | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 0.91 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001452 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 1.31 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001453 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-amide-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001454 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-Imatinib | 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001455 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O4-Imatinib | 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001456 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F | Imidazole derivative | NA | NA | NA | 3.7 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001457 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-GA | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 0.36 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001458 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 0.62 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001459 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-amide-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001460 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-Imatinib | 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001461 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O4-Imatinib | 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001462 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F | Imidazole derivative | NA | NA | NA | 4.7 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001463 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-GA | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 1.12 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001464 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 1.12 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001465 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-amide-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001466 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-Imatinib | 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001467 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O4-Imatinib | 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001468 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F | Imidazole derivative | NA | NA | NA | 3.1 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001469 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-GA | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 0.89 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001470 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 0.57 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001471 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-amide-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001472 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-Imatinib | 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001473 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O4-Imatinib | 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001474 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az | 4-[[2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)imidazol-1-yl]methyl]benzamide | COc1ccc(cc1)c2nc(n(Cc3ccc(cc3)C(N)=O)c2c4ccc(OC)cc4)c5cc(cc(c5)C(F)(F)F)C(F)(F)F | Imidazole derivative | NA | NA | NA | 3.6 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001475 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-GA | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}amino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 0.63 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001476 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(16-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-5,9,13-trioxa-1-azahexadecan-1-yl)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCCOCCCOCCCOCCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 0.72 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001477 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-amide-GD | (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[13-({2-[2-(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)ethoxy]ethyl}carbamoyl)-4,8,12-trioxa-1-azatridecan-1-yl]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate | CO[C@H]1C[C@H](C)CC2=C(NCCOCCCOCCCOCC(=O)NCCOCCOCCNC(=O)C3=CC=C(CN4C(=NC(=C4C4=CC=C(OC)C=C4)C4=CC=C(OC)C=C4)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C3)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | >10 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001478 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O3-Imatinib | 4-{[4-(2-{[(2-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}ethoxy)methoxy]methoxy}ethyl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 4.3 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001479 | 28615625 | Hsp70 | Hsc70 (HSPA8) | Human | Cytosol and nucleus | NA | Antiproliferative activity | Az-O4-Imatinib | 4-{[4-(11-{[4-({2-[3,5-bis(trifluoromethyl)phenyl]-4,5-bis(4-methoxyphenyl)-1H-imidazol-1-yl}methyl)phenyl]formamido}-3,5,7,9-tetraoxaundecan-1-yl)piperazin-1-yl]methyl}-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide | COC1=CC=C(C=C1)C1=C(N(CC2=CC=C(C=C2)C(=O)NCCOCOCOCOCCN2CCN(CC3=CC=C(C=C3)C(=O)NC3=CC(NC4=NC(=CC=N4)C4=CC=CN=C4)=C(C)C=C3)CC2)C(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(OC)C=C1 | Hybrid of HSP70 and HSP90 inhibitor | NA | NA | NA | 4.5 | NA | NA | NA | NA | Nucleotide binding domain | NA | NA | MTT viability assay |
| HSPMDB001480 | 20481474 | Hsp70 | DnaK (Full length) | Bacteria | Cytosol and membrane | Activation of ATPase activity | NA | 115-7c | 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid | CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 | Dihydropyrimidine derivative | 50% at 100 uM | 220 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB001481 | 20481474 | Hsp70 | DnaK (NBD) | Bacteria | Cytosol and membrane | Activation of ATPase activity | NA | 115-7c | 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid | CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 | Dihydropyrimidine derivative | 2 fold at 100 uM | 211 | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | ATPase assay | NA | NA |
| HSPMDB001482 | 20481474 | Hsp70 | DnaK | Bacteria | Cytosol and membrane | Activation of chaperone activity | NA | 115-7c | 4-{5-[(benzyloxy)carbonyl]-4-(2,4-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}butanoic acid | CC1=C(C(NC(=O)N1CCCC(O)=O)C1=C(Cl)C=C(Cl)C=C1)C(=O)OCC1=CC=CC=C1 | Dihydropyrimidine derivative | 2 fold at 1 uM | NA | NA | NA | NA | NA | NA | NA | Nucleotide binding domain | Refolding assay (luciferase) | NA | NA |
| HSPMDB001483 | 20481474 | Hsp70 | DnaK-DnaJ | Bacteria | Cytosol and membrane | Inhibition of ATPase activity (DnaJ stimulated) | NA | 116-9e | 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 | Dihydropyrimidine derivative | 80% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB010219 | 11036084 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (endogenous) | NA | NSC-630668-R/1 | 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate | C(C)OC(=O)NC(=O)C=1C(NC(N(C1)CCCCCCOC(=O)NCCCCCCNC(OCCCCCCN1C(NC(C(=C1)C(NC(=O)OCC)=O)=O)=O)=O)=O)=O | DSG analogs | 48% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB010220 | 11036084 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity (DnaJ stimulated) | NA | NSC-630668-R/1 | 6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexyl N-[6-[6-[5-(ethoxycarbonylcarbamoyl)-2,4-dioxopyrimidin-1-yl]hexoxycarbonylamino]hexyl]carbamate | C(C)OC(=O)NC(=O)C=1C(NC(N(C1)CCCCCCOC(=O)NCCCCCCNC(OCCCCCCN1C(NC(C(=C1)C(NC(=O)OCC)=O)=O)=O)=O)=O)=O | DSG analogs | 51% | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB010221 | 8939938 | Hsp70 | Ssa1p | Yeast | Cytosol | Inhibition of ATPase activity | NA | N-ethylmaleimide | 1-ethylpyrrole-2,5-dione | CCN1C(=O)C=CC1=O | NA | 100% after 60 min | NA | NA | NA | NA | NA | NA | NA | NA | ATPase assay | NA | NA |
| HSPMDB010222 | 30452489 | Hsp70 | Hsp70-HDJ2 | Human | Cytosol | NA | Antiproliferative activity | 116-9e in combination with Hydroxyurea | 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 60% at 40uM 116-9e and 100 uM Hydroxyurea | Luminescence based viability assay |
| HSPMDB010223 | 30452489 | Hsp70 | Hsp70-HDJ2 | Human | Cytosol | NA | Antiproliferative activity | 116-9e in combination with Triapine | 6-{5-[(benzyloxy)carbonyl]-4-{[1,1'-biphenyl]-4-yl}-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl}hexanoic acid | CC1=C(C(NC(=O)N1CCCCCC(O)=O)C1=CC=C(C=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 | Dihydropyrimidine derivative | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 99% at 40uM 116-9e and 100 uM Triapine | Luminescence based viability assay |